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Abstract 
Background of the Study: Drug interaction is now considered a major 
health problem. In this research we have studied potential interactions 
which can occur in patients on long term digoxin treatment with new 
macrolide antibiotics.  
Objectives:  To investigate the effect of new macrolides on the serum 
digoxin level. 
Methods: For this purpose, 120 patients with heart failure or atrial 
fibrillation were enrolled in this study. The patients received digoxin 
treatment 0.25 mg tablet /day. Clarithromycin tablets a dose of 500 mg 
twice a day for 7 days ,roxithromycin tablets in a dose of 300 mg once a 
day for 5days, or azithromycin capsules in a dose of  500 mg  once a day 
for 3 days  were prescribed for these patients to treat infections.Serum 
digoxin , kidney creatinine , liver enzymes levels and electrolytes levels 
were determined and the patients were put under monitoring to observe 
any new symptoms that may occur before and after new macrolides 
administration .  
Results:   The statistical analysis for data obtained in this study showed 
that the new macrolides induced a significant increase in serum digoxin 
level of patients with heart failure or atrial fibrillation (1.975± 0.145to 
3.268 ± 0.115), (1.75 ± 0.114 to 3.177± 0.112), (1.407± 0.115 to 2.581 ± 
0.093) ng/ml respectively.  The classical digoxin toxicity symptoms as 
nausea and vomiting were observed after new macrolides administration. 
Also induced a significant increase in serum creatinine level (1.150± 
0.0865 to 1.900 ± 0.178) (1.152 ± 0.0 67 to 1.656 ± 0.056),(1.2 ± 0.063to  
2.00 ± 0.118 )  mg/dl respectively. 
Patients who were treated with clarithromycin, produced no significant 
effect on the liver function enzymes levels (serum alanine 
aminotransferase (SGPT) ( 9.36 ± 0.522 to 9.058 ±0.559) U/L, aspartate 
aminotransferase (SGOT) ( 20.78 ± 1.837 to 20.69 ± 1.461 ) U/L, direct 
bilirubin ( 0.351  ± 0.021 to 0 .312 ± 0.016) mg/dl, albumin(5.04 ± 0.264 
 to 5.067 ± 0.241) mg/dl, globulin (2.229± 0.212 to 2.192 ± 0.208) mg/dl, 
and total protein(7.269 ± 0.119 to 7.264 ± 0.129) mg/dl, however, it 
significant raise their serum alkaline phosphatase (ALP) (239 ± 6.20 to 
356.5 ± 17.95) U/L and total bilirubin levels (1.026± 0.058 to 1.32 ± 
0.062) mg/dl. 
On the other hand roxithromycin significantly increase serum direct 
bilirubin (0.341  ± 0.0.018 to 0.445  ± 0.053) mg/dl, globulin (2.73 ± 
0.086 to   3.07 ± 0.136) mg/dl, and it significantly decreased serum 
albumin levels (3.762± 0.06 to 3.48 ± 0.065)  mg/dl  probably resulting in 
increase free active digoxin in the blood .But it had no significant effect 
on (SGPT) (12.25± 1.37 to 10.19±1.47) U/L, (SGOT) (21.82 ± 1.81 to 
20.17 ± 1.58) U/L, (ALP )(341.7 ± 16.67 to 372.7 ± 14.32) U/L ,total 
bilirubin(2.627± 0.116 to 2.79 ± 0.143) mg/dl, and total 
protein(6.486±0.0793to 6.559± 0.118)  mg/dl. 
Azithromycin significantly increase (ALP) (303.8 ± 13.85 to 355.7 ± 
15.58) U/L, total bilirubin(1.825± 0.1443 to 2.142 ± 0.162) mg/dl,  
globulin(2.543 ± 0.22 to   3.147 ± 0.198)  mg/dl,  and it significantly 
decrease serum albumin levels(4.515 ± 0.228 to 3.91 ± 0.165) mg/dl. But 
it had no significant effect on (SGPT) (8.602± 0.58  to 8.813 ±  0.523)  
U/L, (SGOT) (21.37 ± 1.42 to 20.12  ± 1.36) U/L  , direct bilirubin(0.347 
± 0.028 to 0.386  ± 0.042) mg/dl  , total protein(7.088± 0.135 to 7.059 ± 
0.134) mg/dl. 
New macrolides significantly increase serum calcium (8.19± 0.09 to 8.79 
± 0.113), (8.3 ± 0.108 to 8.5 ± 0.086) , (8.38 ± 0.106to 8.65 ± 0.113) 
mg/dl and sodium levels(138.5 ± 0.933 to 141.7 ± 0.849) ( 138 ± 0.893 to 
141.9 ± 0.926 ) (138.5 ± 0.821 to 141.5 ± 0.832 ) mmol, but, they 
significantly decrease serum potassium level (4.877± 0.156 to 4.01 ± 
0.105 ) ,(5.0 9 ± 0. 135 to 4.23  ± 0.112 ), (4.765± 0.105 to 4.13  ± 
0.104 ) mmol which was mainly for the arrhythmias. Two ICU patients as 
a case reports for sever interaction due to uncontrolled of arrhythmia 
caused by clarithromycin or roxithromycin  and digoxin interaction. 
 
 Conclusion: Finally, the present study concluded that new macrolides 
significantly increase serum digoxin level and digoxin toxicity.  
 
   ﺍﻟﺨﻼﺼﻪ
  
ﻗـﺩ ﻟﻼﺩﻭﻴﻪ ﺍﻟﺘﻲ ﺘﺅﺩﻱ ﺇﻟﻰ ﻤﺨﺎﻁﺭ ﺍﻟﺘﺄﺜﻴﺭﺍﺕ ﺍﻟﻌﻜﺴﻴﺔ  ﺒﻴﻥ ﺍﻷﺩﻭﻴﺔ ﻤﻥ  ﺍﻟﺩﻭﺍﺌﻲ  ﻴﻌﺘﺒﺭ ﺍﻟﺘﺩﺍﺨل
ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ ﻫﻭ ﺘﻘﻴﻴﻡ ﻭ ﺒﺤﺙ ﻟﺫﻟﻙ ﻜﺎﻥ ﺍﻟﻬﺩﻑ ﻤﻥ  ﺫﻫﺎ ﺒﻌﻴﻥ ﺍﻹﻋﺘﺒﺎﺭﺘﻜﻭﻥ ﻤﻤﻴﺘﻪ ﺇﺫﺍ ﻟﻡ ﻴﺘﻡ ﺃﺨ
ﺴـﺘﺨﺩﻤﻭﻥ ﻥ ﻴﻋﻠﻰ ﺍﺤﺩﻯ ﺃﻫﻡ ﻫﺫﻩ ﺍﻟﺘﺩﺍﺨﻼﺕ ﺒﺨﺎﺼﻪ ﻋﻨﺩ ﻤﺭﻀﻰ ﺍﻟﻘﻠﺏ ﺍﻟﻠﺫﻴﺍﻟﺘﺩﺍﺨل ﺍﻟﺩﻭﺍﺌﻲ 
ﻤﺠﻤﻭﻋـﻪ )  ﻭﻤﺩﻯ ﺘﺄﺜﻴﺭ ﺍﺴﺘﺨﺩﺍﻡ ﺒﻌﺽ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﻪ ﺍﻟﺤﺩﻴﺜـﻪ ﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ ﻜﻌﻼﺝ ﺩﺍﺌﻡ 
 ﻭﺩﻭﺍﺀ( ﻜﺎﻟﻜﻼﺭﻴﺜﺭﻭﻤﺎﻴﺴﻴﻥ ﻭﺍﻟﺭﻭﻜﺴﻴﻤﺎﻴﺴـﻴﻥ ﻭ ﺍﻵﺯﻭﺜﺭﺭﻭﻤﺎﻴﺴـﻴﻥ : ﺍﻟﻤﻜﺭﻭﻻﻴﺩﺍﺕ ﺍﻟﺤﺩﻴﺜﻪ 
ﻟﺩﻯ ﻤﺭﻀﻰ ﻗﺼﻭﺭ ﺍﻟﻘﻠﺏ ﻭﺍﻻﺭﺘﺠـﺎﻑ ﺍﻷﺫﻴﻨـﻲ ﺍﻟـﺫﻴﻥ ﻴﺨﻀـﻌﻭﻥ ﻟﻠﻤﻌﺎﻟﺠـﻪ  ﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ
  . ﺒﺎﻟﺩﻴﺠﻭﻜﺴﻴﻥ
  
ﻤﺭﻴﻀﺎ ﻤﻥ ﻤﺭﻀﻰ ﺍﻟﻘﻠـﺏ ﻤﻤـﻥ ﻴﺴـﺘﺨﺩﻤﻭﻥ ﻋـﻼﺝ ﺘﻁﻭﻉ ﻤﺌﻪ ﻭﻋﺸﺭﻴﻥ -:ﻴﻘﺔ ﺍﻟﻌﻤل ﻁﺭ
ﻜﻼﺭﻭﺜﺭﻭﻤﺎﻴﺴـﻴﻥ  :ﻓﻲ ﺍﻟﻴﻭﻡ ﻤﻊ ﺍﺤﺩ ﺍﻟﻤﻀـﺎﺩﺍﺕ ﺍﻟﺤﻴـﻭﻱ ﻤﺭﻩ ﺒﺎﻟﻔﻡ ﻤﻠﻐﻡ 52.0ﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ 
ﻤﻠﻐﻡ ﻓﻤﻭﻴﺎ ﻤﺭﻩ ﻓـﻲ 003ﺭﻭﻜﺴﻴﺜﺭﻭﻤﺎﻴﺴﻴﻥ  ﻤﻠﻐﻡ ﻓﻤﻭﻴﺎ ﻤﺭﺘﻴﻥ ﻓﻲ ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ ﺴﺒﻌﺔ ﺍﻴﺎﻡ ﺃﻭ005
ﺎ ﻤﺭﻩ ﻓﻲ ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ ﺜﻼﺜﺔ ﺍﻴـﺎﻡ ﻭ ﺘـﻡ ﻤﻠﻐﻡ ﻓﻤﻭﻴ005ﻭﻤﺎﻴﺴﻴﻥ ﺁﺯﻭﺜﺭ ﺍﻟﻴﻭﻡ ﻟﻤﺩﺓ ﺨﻤﺴﺔ ﺃﻴﺎﻡ ﺃﻭ
ﺯﻴﻤﺎﺕ ﺍﻟﻜﺒﺩ ﺍﻟﺤﻴﻭﻴﻪ ﺘﺭﻜﻴﺯ ﻨﺴﺒﻪ ﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ ﻭ ﺍﻟﻜﺭﻴﺎﺘﻨﻴﻥ ﻭﺍﻻﻴﻭﻨﺎﺕ ﻭﺃﺨﻴﺭﺍ ﺍﻨ: ﻗﻴﺎﺱ ﻜل ﻤﻥ
ﺍﻟﻤﺭﻀﻰ ﺘﺤﺕ ﺍﻟﻤﺭﺍﻗﺒﻪ ﻭﺍﻟﻤﻼﺤﻅﻪ ﻋﻨﺩ ﺤﺩﻭﺙ ﺍﻴﺔ ﺸـﻜﻭﻯ ﺍﻭ ﺍﻋـﺭﺍﺽ  ﻜﺎﻥ ﻭﻓﻲ ﺍﻟﺒﻼﺯﻤﺎ 
  .ﺍﻟﺤﺩﻴﺜﻪﺍﺕ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﻜﺭﻭﻻﻴﺩ ﺠﺩﻴﺩﻩ ﻭﻤﺭﺍﻗﺒﺔ ﺍﻟﺘﻐﻴﺭﺍﺕ ﻗﺒل ﻭﺒﻌﺩ ﺍﺴﺘﺨﺩﺍﻡ
  
 -:ﺍﻟﻨﺘﺎﺌﺞ 
ﺒﻌﺩ ﺍﺴﺘﺨﺩﺍﻡ ﺍﻟﻤﻜﺭﻭﻻﻴﺩﺍﺕ ﺍﻟﺤﺩﻴﺜﻪ ﻭﻅﻬﻭﺭ  مﺯﻴﺎﺩﻩ ﺤﻘﻴﻘﻴﻪ ﻓﻲ ﻤﻌﺩل ﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ ﻓﻲ ﺍﻟﺩ   ?
ﺍﻟـﻰ  411.0 ±57.1 ),(511.0 ±862.3ﺍﻟـﻲ 541.0±579.1) ﺃﻋﺭﺍﺽ ﺴـﻤﻴﻪ ﺍﻟﺩﻴﺠﻭﻜﺴـﻴﻥ 
 .ﻲﻋﻠﻰ ﺍﻟﺘﻭﺍﻟ ﻤﺠﻡ /ﻨﺠﻡ (390.0±185.2ﺍﻟﻰ 511.0 ±704.1),(211.0 ±771.3
 ()871.0 ±09.1ﺍﻟـﻰ  5680.0 ± 051.1)ﺯﻴﺎﺩﻩ ﺤﻘﻴﻘﻴﻪ ﻓﻲ ﺘﺭﻜﻴﺯ ﺍﻟﻜﺭﻴﺎﺘﻨﻴﻥ ﻓﻲ ﺍﻟﺒﻼﺯﻤـﺎ  ?
ﺒﻌـﺩ  ﺩﻱ ﻟﺘـﺭ  /ﻤﻠﺠـﻡ  (811.0 ±00.2ﺍﻟﻰ  360.0 ±2.1 ),(65.0 ±656.1ﺍﻟﻰ  76.0 ±251.1
  ﻜﺭﻭﻻﻴﺩﺍﺕ ﺍﻟﺤﺩﻴﺜﻪﻴﺍﺴﺘﺨﺩﺍﻡ ﻤﻀﺎﺩﺍﺕ ﺍﻟﻤ
ﺠﻲ ﺒﻲ )ﺱ ﺍﻷﻨﺯﻴﻤﺎﺕ ﻟﻴﺱ ﻟﻠﻜﻼﺭﻭﺜﺭﻭﻤﺎﻴﺴﻴﻥ  ﺘﺄﺜﻴﺭ ﺤﻘﻴﻘﻲ ﻋﻠﻰ ﻜﻔﺎﺀﺓ ﺍﻟﻜﺒﺩ ﻤﻥ ﺨﻼل ﻗﻴﺎ ?
 ±96.02ﺍﻟﻰ 738.1±87.02( )ﺠﻲ ﺃﻭ ﺘﻲ ),ﻟﺘﺭ /ﻭﺤﺩﻩ   (  955.0 ±850.9ﺍﻟﻰ  225.0±63.9()ﺘﻲ
ﺩﻱ  /ﻤﻠﺠــﻡ( 610.0±213.0ﺍﻟــﻰ 120.0 ±153.0)ﻭﺒﻴﻠــﻭﺭﺒﻴﻥ ﻤﺒﺎﺸــﺭ  (    955.0
 ﻤـﺎ ﻋـﺩﺍ ﺍﻟﺒﻴﻠـﻭﺭﺒﻴﻥ ,ﺩﻱ ﻟﺘـﺭ  /ﻤﻠﺠـﻡ  (142.0 ± 760.5ﺍﻟـﻰ  462.0±40.5)ﺍﻟﺒﻴـﻭﻤﻴﻥ ,ﻟﺘﺭ
ﻭﺍﻨ ــﺯﻴﻡ ﺍﻟﻔﻭﺴ ــﻔﺎﺕ  ﺩﻱ ﻟﺘ ــﺭ /ﻤﻠﺠ ــﻡ ( 260.0±23.1ﺍﻟ ــﻰ  850.0  ±620.1)ﺍﻟﻜﻠ ــﻲ
 .ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲ ﻓﻜﺎﻨﺕ ﺍﻟﺯﻴﺎﺩﻩ ﺤﻘﻴﻘﻴﻪﻟﺘﺭ /ﻭﺤﺩﻩ (59.71 ± 5.653ﺍﻟﻰ 2.6±932)ﺍﻟﻘﻠﻭﻱ
ﺠﻲ )ﻋﻠﻰ ﻜﻔﺎﺀﺓ ﺍﻟﻜﺒﺩ ﻤﻥ ﺨﻼل ﻗﻴﺎﺱ ﺍﻷﻨﺯﻴﻤﺎﺕﺭ ﺤﻘﻴﻘﻲ ﺘﺄﺜﻴ ﻜﺴﻴﺭﻭﺜﺭﻭﻤﺎﻴﺴﻴﻥ ﻭﻟﻴﺱ ﻟﻠﺭ
 ±71.02ﺍﻟﻰ 18.1±28.12( )ﺃﻭ ﺘﻲ  ﺠﻲ),ﻟﺘﺭ /ﻭﺤﺩﻩ   (  74.1 ±91.01ﺍﻟﻰ  73.1±52.21()ﺒﻲ ﺘﻲ
ﺩﻱ  /ﻤﻠﺠـﻡ  ( 350.0 ±544.0ﺍﻟﻰ  810.0 ± 143.0)ﺒﻴﻠﻴﺭﻭﺒﻴﻥ ﺍﻟﻤﺒﺎﺸﺭﻤﺎ ﻋﺩﺍ  ﻟﺘﺭ/ﻭﺤﺩﻩ  (85.1
 ﺩﻱ ﻟﺘـﺭ  /ﻤﻠﺠـﻡ  (631.0± 70.3ﺍﻟـﻰ 68.0±37.2 )ﻭ ﺍﻟﺠﻠﻭﺒﻴﻭﻟﻴﻥ ﻓﻜﺎﻨﺕ ﺍﻟﺯﻴﺎﺩﻩ ﺤﻘﻴﻘﻴـﻪ  ﻟﺘﺭ
  .ﺩﻱ ﻟﺘﺭ /ﻤﻠﺠﻡ (560.0±84.3ﺍﻟﻰ 60.0±267.3) ﻭﺍﻷﻟﺒﻴﻭﻤﻴﻥ ﻓﻜﺎﻨﺕ ﺍﻟﻨﻘﺼﺎﻥ ﺤﻘﻴﻘﻲ
 ﺍﻻﻟﻜﻼﻴﻥ  - :ﻓﻲ ﻜل ﻤﻥ  ﺤﻘﻴﻘﻴﻪ ﻴﻌﻤل ﺍﻵﺯﻭﺜﺭﻭﻤﺎﻴﺴﻴﻥ ﻓﻲ ﺍﺤﺩﺍﺙ ﺯﻴﺎﺩﺓ, ﻤﻥ ﺠﻬﻪ ﺍﺨﺭﻯ  ?
 ± 528.1)ﺒﻴﻠﻭﺭﻭﺒﻴﻥ ﺍﻟﻜﻠﻲ ﻭ  ﻟﺘﺭ/ﻭﺤﺩﻩ( 85.51 ±7.553ﺍﻟﻰ  58.31 ± 8.303)ﻓﻭﺴﻔﺎﺕ ﺍﻟﻘﻠﻭﻱ 
 891.0 ±741.3ﺍﻟﻰ  22.0 ± 345.2)ﻥﺠﻠﻭﺒﻴﻭﻟﻴ ﻭ ,ﺩﻱ ﻟﺘﺭ /ﻤﻠﺠﻡ ( 261.0 ±241.2ﺍﻟﻰ  3441.0
 ±19.3ﺍﻟﻰ 822.0 ± 515.4)ﺍﻨﺨﻔﺽ ﺘﺭﻜﻴﺯﻩ ﻓﻲ ﺍﻟﺒﻼﺯﻤﺎ   ﺒﻴﻨﻤﺎ ﺍﻟﺒﻴﻭﻤﻴﻥ ﺩﻱ ﻟﺘﺭ /ﻠﺠﻡﻤ (
ﻭﺍﻟﺫﻱ ﺃﺩﻯ ﻤﻤﺎ ﺃﺩﻯ ﺇﻟﻰ ﺍﺭﺘﻔﺎﻉ ﻤﺴﺘﻭﻯ ﺘﺭﻜﻴﺯﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ ﺍﻟﺤﺭ  ﺩﻱ ﻟﺘﺭ /ﻤﻠﺠﻡ ( 561.0
ﺍﻟﻰ  85.0±206.8()ﺠﻲ ﺒﻲ ﺘﻲ)ﺑﻴﻨﻤﺎ ﻟﻴﺲ ﻟﻪ ﺗﺄﺛﻴﺮﺣﻘﻴﻘﻲ ﻋﻰ آﻞ ﻣﻦ, ﺇﻟﻰ ﺍﻟﺴﻤﻴﻪﺒﺩﻭﺭﻩ 
  ﻟﺘﺭ/ﻭﺤﺩﻩ (63.1 ±21.02ﺍﻟﻰ 24.1±73.12) (ﺠﻲ ﺃﻭ ﺘﻲ ), ﻟﺘﺭ/ﻭﺤﺩﻩ   (  325.0 ±318.8
 ﺩﻱ ﻟﺘﺭ /ﻤﻠﺠﻡ ( 431.0 ±950.7ﺍﻟﻰ  531.0±880.7)  ﺍﻟﺒﺭﻭﺘﻴﻥ ﺍﻟﻜﻠﻲ,
ﻭﺍﻟﺘﻐﻴﺭﺍﺕ ﺍﻟﺤﺎﺩﺜﻪ ﻨﺘﻴﺠﺔ ﺩﺨﻭل ﺍﻟﻤﺭﻀﻰ ﻓﻲ ﺩﺭﺠﺎﺕ ﻤﻥ ﺴﻤﻴﺔ ﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ ﺒﺴﺒﺏ ﺍﺨﺘﻼل ﻓﻲ  
 90.0 ± 91.8)ﺍﻟﻜﺎﻟﺴﻴﻭﻡ ﺍﻟﺘﻭﺍﺯﻥ ﻟﻤﻌﺩﻻﺕ ﺍﻻﻴﻭﻨﺎﺕ ﻓﻲ ﺍﻟﺠﺴﻡ ﺤﻴﺙ ﺘﻡ ﺍﺭﺘﻔﺎﻉ ﻤﻌﻨﻭﻱ ﻓﻲ ﺘﺭﻜﻴﺯ
 /ﻤﻠﺠـﻡ  ( 311.0 ±56.8ﺍﻟﻰ  601.0 ± 83.8), ( 680.0 ±5.8ﺍﻟﻰ  801.0 ± 3.8) ( 311.0 ±97.8ﺍﻟﻰ 
 ( 629.0 ±9.141ﺍﻟﻰ  398.0 ± 831), ( 948.0 ±7.141ﺍﻟﻰ  339.0 ± 5.831)ﻭﺍﻟﺼﻭﺩﻴﻭﻡ    ﺩﻱ ﻟﺘﺭ
 651.0 ± 778.4)ﺯ ﺍﻟﺒﻭﺘﺎﺴﻴﻭﻡﺒﻴﻨﻤﺎ ﺍﻨﺨﻔﺽ ﺘﺭﻜﻴ  ﻤﻠﻴﻤﻭل(  238.0 ±5.141ﺍﻟﻰ  128.0 ± 5.831) ,
 401.0 ±31.4ﺍﻟـﻰ  501.0 ± 567.4), ( 211.0 ±32.4ﺍﻟـﻰ  531.0 ± 90.5), ( 501.0 ±10.4ﺍﻟـﻰ 
  .ﻓﻲ ﺍﻟﺒﻼﺯﻤﺎ ﻤﻤﺎ ﺃﺩﻯ ﺇﻟﻰ ﺤﺩﻭﺙ ﺍﻻﻀﻁﺭﺍﺏ ﺍﻟﻘﻠﺒﻲ     ﻋﻠﻰ ﺍﻟﺘﻭﺍﻟﻲ  ﻤﻠﻴﻤﻭل(
 
  -:ﺍﻻﺴﺘﻨﺘﺎﺝ 
ﻴﻥ ﻜـل ﻤـﻥ ﻨﺘﻴﺠـﻪ ﻟﻠﺘـﺩﺍﺨل ﺍﻟـﺩﻭﺍﺌﻰ ﺒ  ـﺩﺨﻭل ﺤﺎﻟﺘﻴﻥ ﻤﻥ ﺍﻟﻤﺭﻀﻰ ﻟﻠﻌﻨﺎﻴﻪ ﺍﻟﻤﺭﻜﺯﻩ  ?
ﺍﻨﺘﻅﺎﻤﻴﺔ ﺍﻟﻘﻠـﺏ  ﻭ ﺩﻴﺠﻭﻜﺴﻴﻥ ﻭﻋﺩﻡ ﺍﻟﺴﻴﻁﺭﻩ ﻋﻠﻰ ﺃﻭ ﺭﻭﻜﺴﻴﺜﺭﻭﻤﺎﻴﺴﻴﻥﻜﻼﺭﻭﺜﺭﻭﻤﺎﻴﺴﻴﻥ 
  .ﻭﻀﻌﻑ ﺍﻻﻤﻜﺎﻨﺎﺕ
ﺃﻥ ﺃﺩﻭﻴﻪ ﺍﻟﻤﺎﻜﺭﻭﻻﻴﺩﺍﺕ ﺍﻟﺤﺩﻴﺜﻪ ﺘﺘﺴﺒﺏ ﻓﻲ ﺯﻴـﺎﺩﻩ ﻤﻠﺤﻭﻅـﺔ ﻓـﻲ ﺘﺭﻜﻴـﺯ : ﺨﻼﺼﺔ ﺍﻟﻘﻭل 
ﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ ﻤﻊ ﺘﻬﻴﺌﺔ ﺍﻟﻤﻨـﺎﺥ ﺍﻟﻤﻨﺎﺴـﺏ  ﺍﻟﺩﻴﺠﻭﻜﺴﻴﻥ ﻓﻲ ﻤﺼل ﺍﻟﺩﻡ ﻟﻠﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﻴﺘﻌﺎﻁﻭﻥ
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INTRODUTION & LITERATURE REVIEW  
1. Introduction 
The awareness of drug interaction is of obvious interest to health care 
professionals. The present work comprises of interaction studies of most 
commonly used macrolides i.e. clarithromycin, azithromycin and 
roxithromycin with digoxin .  
The rapid expansion of the macrolide class of antibiotics in recent years has 
resulted in a growing potential for drug interactions between them and other 
pharmacologically active agents. Clinicians are generally aware of such 
interactions and exercise appropriate caution when prescribing. However, 
interactions may be associated with widely used or widely available 
compounds, including over-the-counter preparations (1). 
This increases the burden of responsibility, with all patients being questioned 
carefully and cautioned before antibiotics are prescribed. 
Over the past 20 years, a number of reports have incriminated macrolides as a 
potential source of clinically severe drug interactions (2). However, differences 
have been found between the various macrolides in this regard and not all 
macrolides are responsible for drug interactions. With the recent advent of 
many semi synthetic macrolide antibiotics it is now evident that they may be 
classified into 3 different groups in causing drug interactions.  
The first group, (e.g. troleandomycin, erythromycins) are those prone to 
forming nitrosoalkanes and the consequent formation of inactive cytochrome 
P450-metabolite complexes. The second group (e.g. josamycin, 
flurithromycin, roxithromycin, clarithromycin, miocamycin and 
midecamycin) form complexes to a lesser extent and rarely produce drug 
interactions. The last group (e.g. spiramycin, rokitamycin, dirithromycin and 
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azithromycin) do not form inactivate cytochrome P450 and are unable to 
modify the pharmacokinetics of other compounds (3, 4, 5). 
One of the hazardous interactions of macrolides occurs with cardiac 
glycosides. The first case of digoxin toxicity, on concurrent use with 
erythromycin was reported by Friedman (6).  Later on, many case reports 
incriminated erythromycin to increase digoxin toxicity (7, 8).  
It was found that digoxin concentration increases 4-fold in female patients 
with cardiac failure and atrial fibrillation, six days after receiving treatment 
with erythromycin for otitis media (9). 
 The challenges to clinicians now are to recognize the potential for an 
interaction before antimicrobial therapy is begun, to be able to distinguish 
interaction of minor clinical significance from those of major importance, 
to alter a therapeutic plan that avoids the interaction and to recognize the 
previously unreported ones when they occur. Therefore, a clinical study to 
identify the potential risks resulting from digoxin and macrolide antibiotics 
need to be conducted.  
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2. Macrolide Antibiotics 
2.1 History 
Macrolide antibiotics have been available worldwide for more than 45 years. 
They are generally acknowledged to be one of the safest classes of 
antimicrobial agents used extensively in the treatment of the upper respiratory 
tract and skin structure infections particularly for children and penicillin –
allergic patient (10).  
The macrolide antibiotics include natural members, pro drugs and semi 
synthetic derivatives. These drugs are indicated in a variety of infections and 
are often combined with other drug therapies, thus creating the potential for 
pharmacokinetic interactions (11, 12).  
2.2.Source 
Macrolides are obtained by controlled submerged aerobic fermentations of 
soil microorganisms .Although species of Streptomyces have dominated 
species of Saccharopolyspora, Micromonospora and Strepto verptoverticillium 
are also well represented. New techniques such as enzyme-linked 
immunosorbent assay (ELISA) based assay may prove beneficial for 
discovering new structures(13 ).  
 
3. The Newer Macrolide Antibiotics  
Since the discovery of erythromycin almost 50 years ago, New Zealand has 
acquired three other macrolide antibiotics (azithromycin, Clarithromycin and 
roxithromycin) which may offer advantages over the original agent. (14).   
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The major differences between the newer macrolides and erythromycin are:-   
• Having  a wide  spectrum of activity  
• Generally achieve higher tissue concentrations  
• Having less gastrointestinal side effects  
• less likely to interact with other drugs  
• Having a longer half-life's  
• The dosed less frequently which may therefore aid compliance  
• More Cost (15). 
Interest in the macrolides was renewed in the mid-1970s mostly due to their 
coverage of atypical bacteria (Mycoplasma pneumonia, Legionella 
pneumophila). Since that time the search has continued for compounds that 
would improve on a number of erythromycin's deficiencies, such as 
pharmacokinetics, drug interaction profile, and gastrointestinal intolerance. 
To improve the spectrum of activity and decrease the disadvantages of 
erythromycin, many drugs have been developed, as azithromycin, 
clarithromycin and roxithromycin, dirithromycin and micocamycin.  
The commonly used newer macrolides are as follow: 
4. Clarithromycin 
4.1. Historical development 
Clarithromycin was discovered and patented by Taisho Pharmaceutical Co. 
Ltd. Japan approved by FDA in 1991 (16) and is being marketed by Abbott 
Laboratories. 
Clarithromycin (Biaxin; Clathoromycin; Klacid; Klaricid; Zeclar), a 14-
membered ring macrolide is relatively new semi synthetic derivative of 
erythromycin A with similar spectrum of activity and clinical uses but with 
more consisting absorption and a longer half-life (17). It has a more favorable 
pharmacokinetics profile than erythromycin, which allows twice daily 
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administration and a possible increase in compliance (18, 19). Chemically                   
clarithromycin is 6-O-methyl erythromycin A (19,20), with increased tissue or 
cellular penetration (21).  
 
4.2. Chemistry 
 Many natural and synthetic macrolide antibiotics are in various stages of 
development. All have either a 14- or 16-member macrolactone ring. 
Clarithromycin (methyl-erythromycin), it is semi synthetic compound, has a 
14-member macrolactone ring similar to erythromycin. Clarithromycin differs 
from erythromycin through substitution of a methylated hydroxyl  group at the 
6 position named as:(6-o-methyl-erythromycin A) or (2R,3R, 4S,5R, 6R,8R, 
10R,11R,12S,13R,)  -5-(3-amino-3,4,6-trideoxy-N,N-dimethyl-β-D-
xylohexopyranosyloxy)-3-(2,6-dideoxy-3-C,3-o-dimethyl-α-L-ribo-
hexopyranosyloxy)-13-ethyl-6-methoxy-11,12-dihydroxy-2,4,6,8,10,12-
hexamethyl-9-oxotridecan-13-olide)  (22,23,24,25). The structure of 
clarithromycin  is shown in (Fig. 1):                      
 
Fig. 1: Structure of clarithromycin 
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4.3 Mechanism of Action 
All macrolides block protein synthesis by binding to the 23S-component of 
the 50S-subunit of prokaryotic ribosomes (26, 27). Specifically, they act by 
stimulating dissociation of peptidyl – tRNA from ribosome's during the 
elongation phase of bacterial growth, leading to inhibition of mRNA-
dependent protein synthesis and inhibition of bacterial growth (28).Fourteen-
member macrolides inhibit translocation of peptidyl-t-RNA, and 16-member 
macrolides inhibit peptidyl transferase reactions (14,28). As a class, macrolides 
are generally bacteriostatic although they can have activity against various 
organisms or under specific conditions (29, 30).                                                                                                    
3.5 Microbiology 
Clarithromycin has similar antibacterial coverage for community-acquired 
respiratory pathogens (31, 32).In general, clarithromycin act for most gram-
positive and gram-negative pathogens, including atypical respiratory 
pathogens such as Legionella sp. (33, 34, 35). Mycoplasma  pneumonia (36), and 
Chlamydia pneumonia  (37, 38, 39).  
It is 2 to 10 times more active than erythromycin in several experimental 
animal infection models including most strains of Gram-positive aerobes  
(Staphylococcus aureus , Streptococcus pneumonia , Streptococcal 
pharyngitis, Pyogenes, Listeria monocytogenes ,Streptococcus 
agalactiae,Streptococci Groups C.F&G),Gram negative aerobes (Haemophitus 
infuenzae,Brodetella pertussis,Campylabacter jejuni,Leionella pnemonphila, 
Neisseria gonorrhoeae )and otheraerobes (Mycoplasma pnemonlae)both in 
vitro and in clinical infections(13)  
Clarithromycin is usually bacteriostatic, but it has been shown to be 
bactericidal in high concentration against very susceptible organisms (13) 
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3.6 Pharmacokinetics 
The pharmacokinetic profile of clarithromycin is similar to that of 
erythromycin. However, clarithromycin is rapidly and completely absorbed 
from the gastrointestinal tract, it is the most bioavailable macrolide marketed 
(40, 41). Food delays the absorption of clarithromycin The Tmax ranges from 2-3 
hours, resulting in a Cmax of 2.4-3.5 mg/L after a single 500-mg oral dose 
(42,43).The Vd of clarithromycin into plasma and tissues is similar to that of 
other macrolides, but its retention time is much shorter (intracellular half-life 
5 min) (44). The drug's protein binding ranges from 42-70% (45).On average, 
25% of a systemically available dose is metabolized by CYP3A4 to the active 
metabolite 14-hydroxy-clarithromycin (14-OHC) (46, 47).60% of a dose is 
inactivated by metabolism which is saturable (t 1/2 increase with dose) and 
remainder is eliminated in the urine (48).  
Clarithromycin and 14-OHC both undergo by fecal excretion of both is 
approximately 40%, and urinary excretion ranges from 46-53% (47,49). 
3.7 Therapeutic Uses 
Clarithromycin is effective in sinusitis and otitis media , lung  lesions, 
ventricular dysrthythmias and other chest infection, Listeria monocytogenees, 
Murine listeriosis, Streptococcal pharyngitis.Mycobacterium simiae, 
Mycobacterial infections and other infections (13)  . 
3.8 Adverse Effects  
The adverse effects and toxicities of clarithromycin is similar in type and 
frequency, and their occurrence rates are much lower than those of 
erythromycin (50, 51). The most frequent adverse effects associated with 
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macrolide antibiotics are gastrointestinal (dyspepsia, diarrhea, nausea, 
headache, abdominal cramping).  
Allergic reactions, hepatotoxicity, and ototoxicity are less common .In 
general, all adverse effects are usually of mild to moderate intensity (51, 52, 53, 
54, 55 ). Elevations of liver enzymes, cholestatic jaundice and hepatitis have also 
been reported. 
3.9 Drug Interactions 
A number of drug interactions of clarithromycin with several drugs have been 
reported (56) Clarithromycin is both an inhibitor of CYP3A4 and CYP1A2 (13). 
Both isoforms, particularly CYP3A4, are responsible for the metabolism of 
numerous drugs (13). Therefore, several drug interactions occur with 
clarithromycin like warfarin which is again the most commonly suspected 
interacting medicine, statins, digoxin and anticonvulsants are also represented 
(Table 1). 
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3.10 Dosage and Administration 
Clarithromycin is given orally or by intravenous infusion. Oral dosage 
forms are available as film coated tablets or granules for oral suspension 
(57). The normal adult dosage for clarithromycin is 250-500 mg orally 
twice/day for 7-14 days. The agent is approved for use in children (> 6 
mol) and is dosed by body weight (7.5 mg/kg twice/day for 10 days). 
3.11. Contraindications 
 Clarithromycin should be used with caution if the patient has liver or kidney 
disease, certain heart problems (e.g., QTc prolongation or bradycardia), or a 
mineral imbalance (e.g., low potassium or magnesium levels) (58,59). 
4. Roxithromycin 
Roxithromycin is a semi-synthetic 14-membered ring macrolide antibiotic in 
which the erythronolide A lactone ring has been modified to prevent 
inactivation by gastric acid. Roxithromycin differs from erythromycin A by 
the replacement of the 9-keto group by an etheroxime side chain see Fig. 2. 
Roxithromycin is available under several brand names, for example, Roxl-
150, Roxo, Surlid, Rulide, Biaxsig, Roxar, Roximycin, Tirabicin and Coroxin. 
It is used to treat respiratory tract, urinary and soft tissue infections.  
It is also currently undergoing clinical trials for the treatment of male-pattern 
hair loss (60), and has been tested to possess anti-malarial activity. 
 
4.1 Historical Development 
 Roxithromycin is a semi synthetic macrolide developed in the laboratories of 
Roussel Uclaf.( German pharmaceutical company ) brought out roxithromycin 
in 1987. It is the product of research program aimed at finding a compound 
with the antimicrobial activity of erythromycin and other currently available 
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macrolides, but with far superior pharmacokinetic properties. With the 
synthesis and development of a new macrolide molecule, initially named as 
roxithromycin, trade name RULID (13). It shows a similar range of activity to 
erythromycin but is much more active in vivo and shows good clinical 
potentials (13) 
 
4.2 Chemistry 
Roxithromycin a derivative of erythromycin ,which shows a similar range of 
activity to the later but is more active in vivo (61),Chemically roxithromycin is 
erythromycin9-(O-(2-methoxy ethoxy) ethyl) oxime) (61) ,or erythromycin 9-
(O(2 methoxyethoxy ) methyl ) oxime) 
(3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R)-4-[(2,6-dideoxy-3C,3-o-
dimethyl-α-L-ribo-hexopyranosyl)oxy)14-ethyl-7,2,3trideoxy-10-((E)-((2-
ethoxy)methoxy)imino)-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-
dimethylamino-β-D-xylo-hexopyranosyl)oxy)oxacyclo tetradecan-2-one 
Roxithromycin is a white, crystalline powder, very slightly soluble in water, 
freely soluble in acetone, and alcohol. It is molecular formula is C41H76N2O15 
The structure of roxithromycin shown in (Fig .2): 
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Fig.2: Structure of roxithromycin. 
 
4.3 Microbiology  
 
The antibacterial activity of roxithromycin has extensively been studied 
against a number of Gram-negative and Gram-positive microorganisms, and 
compared with those of other macrolides. Methicillin-resistant Staphylococci, 
which are usually resistant to macrolides are inhibited by roxithromycin at 
readily achievable tissue levels. 
The natural antibacterial spectrum of roxithromycin is essentially the same as 
that of other macrolides and covers against both Gram-negative and Gram-
positive microorganisms. Various microorganisms used were Staphylococcus 
aureus, Enterococcus faecalis, Escherichia coli, Salmonella typhi, Proteus 
vulgaris, Shigella dysentery, Klebsiella pneumoniae and Staphylococcus 
epidermidis (40). 
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4.4 Mechanism of Action 
 Roxithromycin prevents bacteria from growing, by interfering with their 
protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial 
ribosome, and thus inhibits the translocation of peptides. Roxithromycin has 
similar antimicrobial spectrum as erythromycin, but is more effective against 
certain gram-negative bacteria, particularly Legionella pneumophila (56).  
4.5 Pharmacokinetics 
 When taken before a meal, roxithromycin is very rapidly absorbed, and 
diffused into most tissues and phagocytes. Due to the high concentration in 
phagocytes, roxithromycin is actively transported to the site of infection. 
During active phagocytosis, large concentrations of roxithromycin are 
released.Only a small portion of roxithromycin is metabolised. Most of 
roxithromycin is secreted unchanged into the bile and some in expired air. 
Less than 10% is excreted into the urine. Roxithromycin's half-life is 12 hours 
(61). 
4.6 Indications 
Roxithromycin has activity against many pathogens commonly responsible for 
upper and lower respiratory tract infections, for sexually transmitted diseases 
and genital infections and skin and skin structure infection (61).Therefore, it is 
used to treat respiratory tract, urinary and soft tissue infections. It is also 
currently undergoing clinical trials for the treatment of male-pattern hair loss. 
And has been tested to possess anti-malarial activity (60) 
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4.7 Side Effects  
Most common side effects are gastrointestinal disturbances; diarrhea, nausea, 
abdominal pain and vomiting, hyper sensitivity reactions. Less common side 
effects include central or peripheral nervous system events such as headaches, 
dizziness, vertigo, and also the rarely seen rashes, abnormal liver function 
values and alteration in senses of smell and taste (61) 
4.8 Drug Interactions 
Roxithromycin is often considered to have less potential for interactions than 
erythromycin due to its much lower affinity for CYP3A4, but reports to 
ADRAC (Adverse Drug Reactions Advisory Committee) suggest otherwise. 
Of the 737 reports for roxithromycin in the past ten years, 80 have described 
interactions. The majority of these have described interactions with warfarin 
but there are also reports of interactions with anticonvulsants, statins , digoxin 
and cyclosporin .It is probable that the interaction with warfarin has a 
mechanism not involving CYP3A4 (56). 
 
4.9 Dosage and Administration 
In adults the recommended dose to be taken orally is 300 mg, tablet once daily 
at least 25 to 30 minutes before meal or one 150 mg tablet twice daily. In 
pediatrics the dosage in 5 to 8 mg/kg/day by oral route in two divided doses 
before meals and treatment must not be prolonged for more than 10 days .Due 
to the lack of drug accumulation, the daily dose can conveniently be given on 
a bid regimen, which can ensure effective plasma concentration against 
sensitive organisms (61) 
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5. Azithromycin  
Azithromycin is the first macrolide antibiotic belonging to the azalide group. 
Azithromycin is derived from erythromycin by adding a nitrogen atom into 
the lactone ring of erythromycin (62).  
5.1 Historical Development 
From the time that erythromycin was introduced in the United States in 1952, 
it has been used extensively to treat a variety of infectious diseases. The 
usefulness of the oral form of erythromycin has been limited, however, by the 
need for multiple daily dosing and by the drug's erratic bioavailability, acid 
instability, and interactions with a wide range of agents. In 1991, a 
modification to erythromycin produced the next generation of oral macrolide, 
the azalides. Azithromycin (Zithromax; Pfizer, New York, NY), the prototype 
azalide, is a dibasic, 15-member-ring compound that exhibits several 
important chemical and pharmacodynamic characteristics that set it apart from 
erythromycin (63, 64). 
5.2 Chemistry 
Azithromycin's name is derived from the azane-substituent and erythromycin.  
Its  accurate chemical  name  is 2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-
13-[(2,6-dideoxy-3-C-methyl-  3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-
ethyl3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-3,4,6-trideoxy-3-
(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-
15-one.(65).It is molecular formula is C38H72N2O12.The structure of  
azithromycin is shown in ( Figure .3):  
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Fig. 3: Structure of azithromycin. 
5.3 Microbiology 
 Azithromycin has a similar antimicrobial spectrum as erythromycin, but is 
more effective against certain gram-negative bacteria, particularly 
Haemophilus influenzae. Azithromycin resistance has been described (40) and 
is endemic in many areas. 
Azithromycin has been most effective against isolates of the following 
microorganisms: Staphylococcus aureus ,Streptococcus agalactiae 
,Streptococcus pneumoniae,Streptococcus pyogenes ,Haemophilus ducreyi 
,Haemophilus influenzae ,Moraxella catarrhalis ,Neisseria gonorrhoeae 
,Chlamydia pneumoniae ,Chlamydia trachomatis ,Mycoplasma pneumoniae 
,Helicobacter pylori , and Salmonella typhi. 
Azithromycin has been shown to be effective against malaria when used in 
combination with artesunate or quinine; the optimal dose for this is not yet 
known. (119) 
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5.4 Mechanism of Action 
Azithromycin prevents bacteria from growing, by interfering with their 
protein synthesis. Azithromycin binds to the subunit 50S of the bacterial 
ribosome, and thus inhibits the translocation of peptides. Azithromycin has 
similar antimicrobial spectrum as erythromycin, but is more effective against 
certain gram-negative bacteria, particular Hemophilus influenza (65). 
5.5 Pharmacokinetics 
Due to the insertion of methyl-substituted nitrogen in place of the 9A carbonyl 
group in the aglycone ring of erythromycin, azithromycin displays resistance 
to acid-catalyzed degradation and has a 300-fold increase in acid stability 
compared with erythromycin. In addition, azithromycin has improved, more 
predictable absorption (bioavailability 37%); a long half-life (40-hr) for once-
daily dosing; extensive tissue penetration with high intracellular 
concentrations; and enhanced activity against Haemophilus influenza, 
Moraxella catarrhalis, and Mycoplasma pneumonia compared with 
erythromycin. In 1997, the Food and Drug Administration approved the 
intravenous form of azithromycin (66, 67). 
Azithromycin achieves high concentrations in tissue relative to those in 
plasma .It remains largely un metabolized and excreted in the bile and feces. 
In view of its high hepatic excretion, use in patients with liver disease should 
be avoided (120 ). 
Unlike erythromycin, azithromycin is acid-stable and can therefore be taken 
orally without being protected from gastric acids. It is readily absorbed, and 
diffused into most tissues and phagocytes. Due to the high concentration in 
phagocytes, azithromycin is actively transported to the site of infection. 
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During active phagocytosis, large concentrations of azithromycin are released. 
The concentration of azithromycin in the tissues can be over 50 times higher 
than in plasma. This is due to ion trapping and the high lipid solubility.  
Azithromycin's half-life is approximately 2 days, and it's fairly resistant to 
metabolic inactivation. Its main elimination route is through excretion in to 
the biliary fluid, and feces. 
5.6. Therapeutic Uses 
This antibiotic is used for the treatment of infections caused by susceptible 
organisms to azithromycin: in lower respiratory tract infections including 
bronchitis and pneumonia, in skin and soft tissue infections, in otitis media 
and in upper respiratory tract infections including sinusitis apharyngitis / 
tonsillitis. (Penicillin is the usual drug of choice in the treatment of 
Streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic 
fever. Azithromycin is generally effective in the eradication of streptococci 
from the oropharynx (63, 65) . 
5.7 Side Effects 
Most common side-effects are gastrointestinal; diarrhea, nausea, abdominal 
pain, indigestion (dyspepsia) & vomiting. Headache, heart beats 
(arrhythmias), abnormal reaction of the skin to light, usually a rash 
(photosensitivity) Seizures (convulsions), pins and needles (paraesthesia), 
hearing disturbances, pain in the joints, sleepiness, weakness or loss of 
strength (asthenia), dizziness or loss of balance .Yeast infection of the moist 
areas of the body, especially the vagina (candiasis), anxiety, agitation, allergic 
skin reactions and, liver disorder (65). 
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5.8 Drug Interactions 
Drug interaction may occur in patients receiving azithromycin and (antacids, 
carbamazepine,cimetidine, cyclosporin, ergot derivatives, methylprednisolone, 
terfenadine, astemizole ,theophylline , warfarin & zidovudine) . 
Some of the macrolide antibiotics have been reported to impair the 
metabolism of digoxin (in the gut) in some patients. Therefore, in patients 
receiving azithromycin and digoxin the possible of raised digoxin level should 
be borne in mind, and digoxin levels monitored (62). 
5.9 Contraindications 
Azithromycin is contraindicated in patients with a known hypersensitivity to 
azithromycin or any of the macrolide antibiotics, or to any other ingredient of 
the preparation (68). 
5.10 Dosage and Administration 
Azithromycin should be given as a single daily dose. In common with many 
other antibiotics, azithromycin should be taken at least one hour before or two 
hours after food. The period of dosing with regard to infection is given below: 
for treatment of sexually transmitted diseases caused by chlamydia 
trachomatis the dose is 1 gram given as single dose. For the other indications, 
the dose is 1500mg, which should be given 500mg (2 capsules ofazithromycin 
250 mg) daily for 3 days. Alternatively, the 1500 mg dose can be given over 5 
days with 500 mg given on day 1, then 250 mg daily ondays 2 to 5 (69). 
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6. Cardiac Glycosides (Digoxin) 
Digoxin, the modern derivative of digitalis which is one of the oldest known 
drugs in western medicine .It is a purified cardiac glycoside extracted from the 
foxglove plant, Digitalis lanata  (70) .Its corresponding aglycone is digoxigenin 
, and its acetyl derivative is acetyl digoxin. Digoxin is widely used in the 
treatment of various heart conditions, namely a trial fibrillation, atrial flutter 
and sometimes heart failure that cannot be controlled by other medication. (71, 
72, 73). It has a narrow therapeutic index and multiple, well-known drug 
interactions. 
6.1 History and Sources 
Digoxin is a compound in the drug family known as cardiac glycosides or 
cardenolides. It contains a five- or a six-membered lactone ring that is 
attached to a steroid nucleus at position 17. Digoxin originates from the leaves 
of the purple foxglove (Digitalis purpurea) which plant extracts is a discovery 
attributed to English physician William Withering in 1785, these compounds 
have been used medicinally for more than 2,000 years (71,72,73, 74,75,77,78,79) 
6.2 Chemistry   
Digoxin has the molecular formula C41H64O14, a molecular weight of 780.95 
and melting and decomposition points above 235oC. The drug is practically 
insoluble in water and in ether; slightly soluble in diluted (50%) alcohol and in 
chloroform; and freely soluble in pyridine. Digoxin powder is composed of 
odorless white crystals (77,104,106). 
Digoxin has the chemical name: (3Beta,5B,12B)-3-[(0-2,6-dideoxy-B-D-ribo-
hexopyranosyl-(1 to 4)-0- 2,6-dideoxy-B-D-ribo-hexopyranosyl-(1 to 4)-2,6 
dideoxy-B D-ribo-hexopyranosyl)oxy]-12,14-dihydroxycard-20(22)-enolide, 
The structure, shown in (Figure .4):                                     
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Fig .4:Structure of cardiac glycoside 
6.7 Mechanism of Action 
Digoxin binds to a site on the extracellular aspect of the α-subunit of the 
Na+/K+ ATPase  pump in the membranes of heart cells (myocytes) and 
decreases its function. This causes an increase in the level of sodium ions in 
the myocytes , which then leads to a rise in the level of calcium ions. The 
proposed mechanism is the following: inhibition of the Na+/K+ pump leads to 
increased intracellular Na+ levels, which in turn slows down the extrusion of 
Ca2+ by the sodium-calcium exchanger that relies on the high Na+ gradient. 
When the digoxin   effects on the parasympathetic nervous system, leads to a 
decrease in heart rate. Increased amounts of Ca2+ are then stored in the 
sarcoplasmic reticulum and released by each action potential, which is 
unchanged by digoxin. This leads to increased contractility of the heart. 
Digoxin also increases vagal activity via its action on the central nervous 
system, thus decreasing the conduction of electrical impulses through the AV 
node. This is important for its clinical use in different arrhythmia of action (84) 
is shown in (Figure .5):                      
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Fig .5: Inotropic effect of digoxin 
6.8 Pharmacokinetics  
Digoxin is usually administrated by oral or intravenous routes. Digoxin is well 
absorbed, with peak serum concentrations occurring within one hour. A large 
volume of distribution (4–7 l/kg) reflects that digoxin concentrates in the 
tissues, with the active site being within myocardial and other cells. 
Redistribution from serum to tissue takes at least eight hours. Digoxin 
concentrations should be measured at least six to eight hours following an oral 
dose of digoxin and ideally when concentrations have reached steady-state. 
Understanding of the reasons behind these recommendations requires an 
understanding of the pharmacokinetic profile of digoxin. Digoxin is 
metabolized by the liver (79).  It elimination is predominantly renal in nature 
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(the fraction excreted unchanged in the urine is 0.6 to 0.9) and is dependent 
upon glomerular filtration and P-glycoprotein-mediated active tubular 
secretion. A long half-life of at least 36 h (in normal renal function) results in 
steady-state concentrations taking at least five days to be achieved (it takes 
four half-lives to achieve >90% of steady-state concentrations) (80). 
 
6.9 Indications and Uses 
Today, the most common indications for digoxin are probably atrial 
fibrillation and a trial flutter with rapid ventricular response, but beta- or 
calcium channel- blockers should be the first choice (81, 82, 83). High 
ventricular rate leads to insufficient diastolic filling time. By slowing down 
the conduction in the AV node and increasing its refractory period, digoxin 
can reduce the ventricular rate. The arrhythmia itself is not affected, but the 
pumping function of the heart improves owing to improved filling. 
The use of digoxin in heart problems during sinus rhythm was once standard, 
but is now controversial. In theory the increased force of contraction should 
lead to improved pumping function of the heart, but its effect on prognosis is 
disputable and other effective treatments are now available. Digoxin is no 
longer the first choice for congestive heart failure, but can still be useful in 
patients who remain symptomatic despite proper diuretic and ACE inhibitor 
treatment. It has fallen out of favor because it was proven to be ineffective at 
decreasing morbidity and mortality in congestive heart failure. It is shown to 
increase quality of life, however. Digoxin is also used as a standard control 
substance to test for p-glycoprotein inhibition (84) 
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? Atrial Fibrillation:  
Even in the absence of congestive heart failure, digitalis is indicated in most 
cases of a trial fibrillation, even though it has no effect on the condition per. 
second. The aim of digitalis therapy is to: 
a)  Restore the myocardial efficiency. 
b)  Reduce the ventricular rate through slowing of conduction and     
Prolongation of the A-V node. 
c)  Eliminate the pulse deficit (85, 86, 87, 88) 
? Atrial Flutter:  
Digitalis is the drug of choice in a trial flutter whether or not heart 
Failure is present (80). 
? Paroxysmal A trial Tachycardia (PAT):  
Digoxin may convert PAT to sinus rhythm by slowing conduction through the 
AV node. If heart failure has ensued or paroxysm recurs frequently, digoxin 
should be continued (80).  
? Heart Failure: Digoxin is more effective in congestive heart failure due 
to:  
? Increase cardiac conductivity and intra ventricular pressure. 
? Decreasing heart rate which decreases cardiac work,  
? Increasing mechanical efficiency  
? Diuretic action which decreases blood volume and pre-load (80, 89, 90, 91). 
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6.10 Dosage of Digitalis 
Digoxin preparations are commonly marketed under the trade names Lanoxin, 
Digitek, and Lanoxicaps. It is also available as a 0.05 mg/ml oral solution and 
0.25 mg/ml or 0.5 mg/ml inject able solution. Which is usually given by 
mouth, but can also be given by IV injection in urgent situations (the IV 
injection should be slow, heart rhythm should be monitored). The half life is 
about 36 hours; digoxin is given once daily, usually in 125 µg or 250 µg 
dosing. In patients with decreased kidney function the half life is considerably 
longer, calling for a reduction in dosing or a switch to a different glycoside 
(such as digitoxin which although having a much longer elimination half-life 
of around 7 days, is mainly eliminated from the body via the liver, and thus 
not affected by changes in renal function). 
 
Effective plasma levels are fairly well defined, 1-2.6 nmol/l. In suspected 
toxicity or ineffectiveness, digoxin levels should be monitored. Plasma 
potassium levels also need to be closely controlled Digitalis therapy 
(digitalization) involves the maintenance of an optimum concentration of the 
drug in the blood. This corresponds to 0.8- 2.0 ng /ml for digoxin. Higher 
levels for either drug are toxic (92). 
 
6.11 Adverse Reactions  
The occurrence of adverse drug reactions is common, owing to its narrow 
therapeutic index (the margin between effectiveness and toxicity). Adverse 
effects are concentration-dependent, and are rare when plasma digoxin 
concentration is <0.8 µg/L.(119) They are also more common in patients with 
low potassium levels (hypokalemia), since digoxin normally competes with 
K+ ions for the same binding site on the Na+/K+ ATPase pump. The adverse 
effects of digoxin can be either cardiac or non-cardiac. 
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Common adverse effects (≥1% of patients) include: loss of appetite, nausea, 
vomiting, diarrhea, blurred vision, visual disturbances (yellow-green halos), 
confusion, drowsiness, dizziness, nightmares, agitation, and/or depression, as 
well as a higher acute sense of sensual activities (119). 
 Less frequent adverse effects (0.1%–1%) include: acute psychosis, delirium, 
amnesia, shortened QRS complex, a trial or ventricular extra systoles, 
paroxysmal a trial tachycardia with AV block, ventricular tachycardia or 
fibrillation, heart block (84) .Digoxin can cause any kind of cardiac rhythm 
disturbance, especially heart block and ectopic arrhythmias, particularly in 
combination which is cardiac adverse effects (93, 94). 
6.12 Contraindication 
Digitalis glycosides are contraindicated in ventricular fibrillation (80).  
 
6.13 Drug Interactions of Digoxin 
Drug-Drug Interactions (DDI) occurs when the effect of one drug is changed 
by the presence of another drug. The outcome can be harmful if the DDI 
causes an increased toxicity of the other drug. However, a reduction in 
therapeutic efficacy due to a DDI may be just as harmful as an increase. 
Besides their beneficial effects, drugs may also induce illness and death (1). 
 
A drug interaction is defined as the pharmacologic or clinical response to the 
administration of a drug combination different from that anticipated from the 
known effects of the two agents when given alone. The drug affected by the 
interaction is called the “object drug” and the drug causing the interaction is 
called the “precipitant drug” (95). 
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Drug interactions may lead to a loss of therapeutic effect or toxicity; they may 
also benefit the patient. (81, 82) 
The outcome can be harmful if the DDI causes an increased toxicity of the 
drug. However, a reduction in therapeutic efficacy due to a DDI may be 
just as harmful as an increase. Besides their beneficial effects, drugs may 
also induce illness and death (1). In addition to DDI, there are a variety of 
other substances that can alter the pharmacokinetics and/or effect of drugs 
(81, 82). 
7. Drug Interaction 
7.1 How Are the Drug Interactions a Big Problem? 
Americans filled a record 2.4 billion prescriptions in 1996. Although this may 
be seen as a good thing, it also can present problems. There has never before 
been so much opportunity for confusion, drug interactions, and side effect (95). 
 
Epidemiological data relating to the negative clinical outcome of Drug-Drug 
Interactions are rare and therefore we use the expression potential (p) DDI. 
Hamilton et al. pointed out that exposure to( p)DDIs was associated with a 
significantly increased risk of hospitalization (96). According to Pir mohamed 
et al., one percent of all hospital admissions were caused by DDIs, 
corresponding to 16% of all patients admitted with Adverse Drug Reactions 
(ADRs) (97). 
In a Swiss hospital, Lepori et al. showed that 21% of all drug-related hospital 
admissions were caused by DDIs (1.3% of all admissions) (99,100). The 
incidence of drug interactions varies widely in the literature ranging from 2.2–
70.3% (101,102). It is increased in the elderly, especially in those patients who 
are confined to nursing homes, and patients with multiple organ dysfunctions. 
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8. Digoxin & Macrolides Drug Interactions and Toxicity 
A potential drug-drug interaction between digoxin and certain antimicrobial 
agents in patients with congestive heart failure (CHF) , or atrial fibrillation 
occasionally precipitates digoxin toxicity .    
Toxicity due to cardiac glycosides is a common and potentially life-
threatening problem. Treatment of such toxicity presents unique challenges 
to the pre -hospital provider, because many of the tools commonly used to 
treat patients in the field may lead to disaster if inappropriately applied. But 
with better understanding of the mechanism of digitalis toxicity, pre-
hospital providers can avoid pitfalls of treatment and render lifesaving care 
(104,105) 
Diagitalis toxicity occurs in 5-20% of all patients being treated with cardiac 
glycosides, because the therapeutic index is low (104). 
Digoxin has a very narrow therapeutic range which means that the patient can 
easily have too much or too little of the drug on board. Over use of 
medications and toxic ranges in patients with heart disease are relatively close, 
toxicity during chronic use may result from an accidental overdose, 
unpredictable changes in kidney function or electrolyte imbalance (104). The 
single most frequent cause of intoxication is the concurrent administration of 
diuretics that cause depletion of K+ (105). 
 
Most of the cases of digitalis toxicity occur during the course of chronic 
therapy (therapeutic toxicity). Acute toxicity is less common. (106).   as might 
be expected from the mode of action of digitalis, the manifestations of toxicity 
are varied and can involve most organ systems in the body (107).  
Digoxin toxicity often presents with gastrointestinal side effects such as 
nausea, vomiting or anorexia. Other side effects include cardiac rhythmias, 
visual disturbances and drowsiness (108). The most important toxic effects, in 
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terms of risk to the patient are those that involve the heart. If unrecognized or 
improperly treated, such reactions are frequently fatal (105) 
. 
In 10 years from 1995 to 2004, ADRAC (Adverse Drug Reactions Advisory 
Committee) received 31 reports of a suspected interaction out of the 597 
reports involving Erythromycin. The basis for these interactions is considered 
to be cytochrome P4503A, particularly 3A4, and also p-glycoprotein, 
particularly for Digoxin(61). See Table (1) page 8. 
 Roxithromycin is often considered to have less potential for interactions than 
Erythromycin due to its much lower affinity for CYP3A4, but reports to 
ADRAC suggest otherwise. Of the 737 reports for roxithromycin ten years, 80 
have described interactions. The majority of these have described interactions 
with warfarin but there are also reports of interactions with anticonvulsants, 
statins, digoxin and cyclosporin. It is probable that the interaction with 
warfarin has a mechanism not involving CYP3A4 . 
On the otherhand clarithromycin , is  a potent inhibitor of CYP3A4, has a 
similar level of reported interactions, with 18 out of 193 reports. Warfarin is 
again the most commonly suspected interacting medicine, and statins and 
anticonvulsants are also represented (61).  
But azithromycin is also considered to have little potential for interactions but 
of the 111 reports received for this medicine, 6 have described interactions 
with either warfarin or tacrolimus. (61) 
Prescribers should be aware of the potential for interactions with all of the 
macrolides, especially with those medicines known to be subject to 
interactions such as warfarin, digoxin, anticonvulsants, and immune 
suppressants e.g. tacrolimus, many of which also have a low therapeutic 
index. 
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8.1 Mechanism of Drug Interaction with New Macrolides and 
Digoxin 
Concurrent therapy with oral antibiotics and digoxin has been associated with 
changes in serum digoxin concentration particularly with macrolides. 
Introduction of newer macrolides with structural modifications resulted in 
compounds with not only varying antibacterial activity but also variability in 
their potential for interactions with other drugs (9).  
There have been several reports of patients taking digoxin and macrolides 
simultaneously in whom serum digoxin concentrations rose and some 
developed digoxin toxicity (112,113). Hence, monitoring the clinical symptoms 
of digoxin toxicity (i.e., arrhythmias, nausea, vomiting, and altered visual and 
mental status) along with serum concentrations when digoxin and new 
macrolides used concurrently urgently needed. This is especially important in 
patients whose plasma digoxin concentrations are maintained at the high end 
of the therapeutic range as in patients with atrial fibrillation (111).   
Several mechanisms have been proposed to explain this interaction between 
digoxin and new macrolides. One hypothesis is that in these patients, 
macrolides kill off most of the intestinal bacteria, especially Eubacterium 
lentum, a microorganism that is capable of metabolizing digoxin to inactive 
dihydro (reduced) metabolites (DRM) is accomplished by intestinal bacteria in 
humans. It has been estimated that this metabolic pathway for digoxin 
represents a substantial fraction of the total digoxin metabolism in 10% of the 
general population (103,109). 
A second mechanism that is possibly involved in this interaction is inhibition 
of P-glycoprotein which decreases the elimination of digoxin. Macrolides 
inhibit P-glycoprotein in the intestine and kidney, with a consequent net 
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increase in intestinal drug absorption and a reduction in active tubular 
secretion (110, 111), as shown in Figure.6  
 
Fig. 6: P-glycoprotein and digoxin 
In the seventies of the 20th century, intestinal metabolism was already 
reported P-glycoprotein  and CYP3A4 are colocalised in intestine, where they 
act together to limit the drug absorption into portal circulation and to decrease 
plasma drug concentrations (191).  
Although the liver has long been thought to play the major role in drug 
metabolism, many studies about effect of the metabolic capacity of the 
intestine has been increasingly recognized (191). 
CYP enzymes play a central role in the metabolism of drugs, and inhibition or 
induction of these enzymes can alter the plasma concentrations and effects of 
their substrate drugs. Inhibition of CYP enzymes has been considered to be 
the most common cause of harmful drug-drug interactions (130). Inhibition of a 
drug-metabolizing enzyme can lead to decreased clearance and increased 
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plasma concentrations of its substrate compound, thus increasing the 
likelihood of adverse effects and toxicity, as CYP enzyme inhibition usually 
occurs rapidly, even after a single dose of Inhibitor (130). 
According to above, the third mechanism is that macrolides interact mainly 
through inhibition of cytochrome P450 microsomal enzymes particularly the 
CYP1A2 and CYP3A4 (3, 4, 81, 111).  
Yamazaki and Shimada et al study showed that the N-demethylamine 
derivative (M3) of roxithromycin is a more potent inhibitor of CYP3A4, after 
activation by CYP3A4 itself, than is the parent drug roxithromycin. Formation 
of inhibitory P450zFe21-metabolite complexes was shown to be required for 
the inhibitory action (127). 
  
The previous hypothesis from rat studies, that formation of a nitrosoalkane 
derivative that attacks the P450 enzyme is critical for potent inhibition is 
consistent with the results of this study using human enzyme preparations. 
The weak abilities of roxithromycin to inhibit CYP3A4 may be the result of 
the slower metabolism of this compound to M3 and other metabolites in 
humans (127) 
Interaction results in elevated serum concentrations of drugs that usually are 
cleared by the hepatic CYP450 oxidizing system. There have been several 
reports of patients taking digoxin and clarithromycin simultaneously in whom 
serum digoxin concentrations rose; some developed digoxin toxicity (108,111). 
Also hypoalbuminemia induced the free active digoxin in blood (114). 
There are other theories as to why macrolides increase serum digoxin 
concentrations?  One theory suggests that macrolides may affect gut motility 
and thereby increase the bioavailability of digoxin; however this less likely as 
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other prokinetic agents have been shown to decease the bioavailability of 
digoxin (110).It is also possible that a disease state such as acute infection will 
have an effect on the CYP450 enzyme system. Drug metabolism can be 
slowed by interferon-related suppression of CYP450 activity (82).Others 
propose a different mechanism of interaction, which involves macrolide 
inhibiting P-glycoprotein-mediated tubular secretion of digoxin (111). Also the 
patients with hypoalbuminemia will have freer digoxin or active drug 
available so that lead to digoxin toxicity (114). 
In 1993, a series of studies identified a mechanism that appears to underline 
the digoxin interaction. One of the most widely studied drug interactions is the 
interaction between digoxin and macrolides (115). 
Although dramatic advances have been made in the study of drug 
interaction mechanisms over the past few decades, there is still much to 
learn. Thus, many of the mechanism concepts useful today will be refined 
in the future, yielding a picture closer to the truth. It also should be kept in 
mind that for some drug-drug interactions more than one mechanism may 
be occurring simultaneous (116,117). 
 
Patients who receive the combination almost always will have a significant 
elevation in their digoxin plasma concentrations and can suffer digoxin 
induced toxicity, including arrhythmias, anorexia, altered color vision, and 
mental changes. Several prospective studies of the interaction were 
published, noting a 2 -fold increase in digoxin concentrations following the 
co administration of macrolidses. Some investigators noted a reduction in 
digoxin renal and total body clearance, the underlying mechanism for these 
interactions remained undefined (112). 
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Several studies have shown that clarithromycin induced digoxin toxicity "Two 
cases of clarithromycin-induced digoxin toxicity" was reported  by   Guerriero 
et al .  Two patients experienced clarithromycin-induced digoxin toxicity. 
Both had stable renal function within normal limits and had been maintained 
on a consistent dosage of digoxin. Administration of clarithromycin to patients 
receiving long-term digoxin therapy may induce digoxin toxicity. When 
concomitant therapy is employed, patients should be closely monitored for 
clinical signs and symptoms of digoxin toxicity, and digoxin concentrations 
should be measured to avoid it (120). 
 
On the other hand Nawarskas et al reported " Digoxin toxicity secondary to 
clarithromycin therapy"   This  case report of digoxin poisoning following the 
co-administration of digoxin and clarithromycin in a 28 year old male is 
described. Since the aetiology of chronic digoxin poisoning is often unclear, 
clinicians should be aware of the potential drug-drug interaction between 
digoxin and clarithromycin (121 ) 
"Clarithromycin-induced digoxin intoxication"was anather  studies by 
Laberge et al  in this studies a 78-year-old white man with ischemic 
cardiomyopathy and chronic renal insufficiency was admitted 4 days after 
being prescribed clarithromycin for a suspected episode of bronchitis. He 
reported weakness, asthenia, and gastrointestinal symptoms; the digoxin 
serum concentration was measured at 3.89 ng/mL. The patient recovered 
uneventfully after digoxin and clarithromycin were discontinued ( 122) 
" Clarithromycin-induced digoxin toxicity" : a case was reported and a review 
of the literature was reported by Rashkow et al . A 70-year-old woman with a 
history of atrial fibrillation, on digoxin, presented with nausea, vomiting, and 
dizziness two days after initiation of clarithromycin therapy the patient was 
admitted to the hospital and digoxin and clarithromycin were discontinued. 
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The patient's symptoms were resolved within 24 hours and her serum digoxin 
level was 1.9 on the second hospital day. A review of recent literature 
suggests  that  c lar i thromycin may induce digoxin toxici ty ( 1 2 5 ) 
" Roxithromycin-induced digoxin toxicity" was also reported. A 76-year-old 
woman presented with digoxin toxicity four days after starting a course of 
roxithromycin. In 10%-15% of the population, digoxin is degraded 
extensively by bacteria in the gastrointestinal tract, and antibiotic-induced 
changes in the bacterial flora may lead to digoxin toxicity was the case which 
reported by Corallo and Rogers( 123). 
 
Tsutsumi et al reported also The effect of erythromycin and clarithromycin on 
the pharmacokinetics of intravenous digoxin in healthy volunteers. The 
authors investigated the effect of erythromycin and clarithromycin on the 
pharmacokinetics of intravenously administered digoxin (0.5 mg) in healthy 
subjects. Nine male subjects participated in three studies (digoxin alone, 
digoxin with erythromycin, and digoxin with clarithromycin) In conclusion; 
neither erythromycin nor clarithromycin has a significant effect on serum 
digoxin disposition after an intravenous administration. Renal digoxin 
excretion is not inhibited but rather enhanced by both macrolides (124). 
In this reasech we have described potential interactions between drugs 
commonly used in clinical practice with the development of life threatening 
adverse reactions. This case gives a better perspective of the adverse drug 
interactions which can occur in patients on long term digoxin with 
introduction of macrolide antibiotics. Prescribing physicians should be aware 
of possible drug interactions when starting  a new drug in patients on digoxin 
therapy 
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The goal of this study was to investigate patients concurrently receiving 
digoxin and macrolides who exhibited serum digoxin concentration above the 
therapeutic range because of a likely interaction between both drugs, and 
whether digitalis intoxication ensued.  
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Aims of the study 
  
General objective 
The aim of this study is to evaluate the effect of new macrolides 
(clarithromycin ,  azithromycin & roxithromycin on serum digoxin level.  
 
Specific objective 
The specific aims of this thesis are to study the following aspects of the 
macrolides- digoxin interaction:  
? Symptoms of digoxin toxicity 
? Kidney function (creatinine level). 
? Liver function (serum total and direct bilirubin, albumin , total  protein, 
alkaline phosphatase, alanine aminotransferase (ALT) (SGPT) ,aspartate 
aminotransferase (AST) (SGOT) and globulin ). 
? Elecrolytes (sodium, potassium and calcium). 
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  Materials & methods 
    1. Materials 
          1.1 Drugs 
• Digoxin crystalline 0.25 mg tablet, (Gold eon Richter LTD.  Hungary) 
• Clarithromycin 14 OH  500 mg tablet, ( Dar Al DAWA , Jordan)  
•  Azithromycin dihydrate  500 mg capsule , ( Alkan Pharm , Egypt)  
• Roxithromycin 300 mg tablet, (Cipla LTD, India). 
1.2 Chemicals & Kits      
• IMx Digoxin assay kit (Abbott Laboratories Diagnostics Division , USA.)  
• Creatinine  Human Kit, ( Human Gesellschhaft, Germany) 
• Total and Direct Bilirubin  Kit, ( Spinreact , S.A. Spain) 
• Glutamic Oxaloacetic Transferase  (SGOT) activity  kit,  
             ( Randox Labratories Ltd., Northern Ireland) 
• Glutamic Pyruvic Transferase  (GPT) (ALT) activity kit ( Spinreact , S.A. Spain). 
• Alkaline Phosphtase (ALP) kit, ( Randox Labratories Ltd., Northern Ireland)  
 
•  Total protein kit,  ( Spinreact , S.A. Spain) 
• Albumin kit, ( Spinreact , S.A. Spain) 
• Calcium Human Kit, ( Human Gesellschhaft  ,Germany) 
• Potassium kit, ( Spinreact , S.A. Spain) 
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1.3 Patients 
120 patients 68 male (M) and 52 female (F), their ages were between (21- 
96 years), using digoxin and new macrolides (clarithromycin,azithromycin   
and roxithromycin) participated in this study; the patients were approached 
by specialist, in collaboration with Ibn-sina hospital, Mukalla city, Yemen  
Inclusion criteria:   
1- Patients under digoxin treatment and using new macrolides as 
antibiotic.  
2- Patients with heart failure or atrial fibrillation 
3- Ages (21- 96 years) 
Exclusion criteria:    
1. Patients with liver or kidney disease 
2. Ages less than (21 years) and more than (96 years) 
The patients, first evaluated clinically for fitness, and then informed about 
the nature of the study. The consent were taken from each patient before the 
study, in which he/she signed to be a volunteer in the study without any 
obligation to the study team (sheet No1, see Appendex).  
After that, volunteers were randomly allocated to the following groups: 
Group A: patients under digoxin therapy (0.25 mg tablet / day), were given 
clarithromycin in a dose of 500 mg tablet twice a day for 7 days.  
Group B: patients under digoxin therapy (0.25 mg tablet / day), were given 
azithromycin in a dose of 500 mg capsule once a day for 3 days. 
 Group C: patients under digoxin therapy (0.25 mg tablet / day), were 
given roxithromycin in a dose of 300 mg tablet once a day for 5days.          
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The patients in these groups were under monitoring and clinical evaluation, 
to observe any new symptoms after the useof clarithromycin or 
azithromycin or roxithromycin therapy and mention a serious ICU patients 
as a case reports.  
2. Methods 
2.1 Study Design  
The study is a prospective comparative drug study.  
The following parameters before and after clarithromycin , azithromycin or 
roxithromycin administration were determined:  
? Serum digoxin level. 
? Serum creatinine level. 
?  Serum liver function tests (total and direct bilirubin, albumin, serum 
total protein, alkaline phosphatase,  alanine aminotransferase (ALT) 
(SGPT), aspartate aminotransferase (AST) (SGOT) and globulin ). 
? Electrolytes levels (sodium, potassium, and calcium). 
• Blood sample collection 
10 ml venous blood sample was collected twice from each volunteer using 
digoxin,  before and after oral administration of clarithromycin in a dose 
500 mg capsule for 7 days , azithromycin in a dose 500 mg capsule once a 
day for 3 days  or roxithromycin in a dose 300 mg tablet once a day for 5 
days  On the first day, blood samples were obtained before the digoxin dose. 
Also, blood samples were collected  on 7thday   of the last dose of 
clarithromycin and on the 3rd day of last dose of azithromycin , and  on 5th 
of the last dose of roxithromycin in a dose 300 mg tablet a day for 5 days 
.Blood samples were collected at least 6 h after an oral dose of digoxin and 
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clarithromycin ,azithromycin , or roxithromycin.. The samples were 
centrifuged at 2000 r.p.m., and stored at -20C until analyzed.  
2.2 Laboratory Assessment  
2.2.1 Determination of Serum Digoxin Level 
Serum digoxin level was determinated by using  the IMx digoxin assay. The 
IMx Digoxin assay is based on the Microparticle Enzyme Immunoassay 
(MEIA) technology(131) . 
Therapeutic normal value of serum digoxin level:  (0.8-2.0 ng /ml)  
Principle: 
The IMx Digoxin assay was based on the Micro particle Enzyme 
Immunoassay (MEIA) technology. 
In this test, the following steps were followed:  
*   The probe / electrode assembly delivers the sample and Antidigoxin 
Coated Micro particles to the incubation well of the reaction cell. 
* The digoxin binded to the Anti-digoxin Coated Micro particles forming 
an "antibody-antigen" complex. 
* An aliquot to the reaction mixture containing the "antibody- antigen" 
complex bound to the microparticales was transferred to the glass fiber 
matrix. The microparticales binded irreversibly to the glass fiber matrix. 
* The digoxin: Alkaline Phosphatse Conjugate was dispensed onto the 
matrix and binded to the available sites on the Anti-digoxin Coated 
Microparticales. 
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* The matrix was washed to remove unbound materials. 
* The substrate, 4-Mthylumbelliferyl Phosphate, was  added to the matrix 
and the fluorescent product was measured by the MEIA optical assembly. 
Reagents: 
Reagent pack          
B1 Anti-digoxin (Rabbit) Coated Micro particles in Tris buffer with protein 
stabilizers. Minimum concentration: 0.0001%. Preservative: Sodium Azide. 
B2 Digoxin:Alkaline Phosphatase Conjugate in Tries buffer with protein  
stabilizers and surfactant.   
Minimum concentration: 0.05 (µg/ml) .     Preservatives: Sodium Azide and 
anti-microbial agent. 
B3 4-Methylumbelliferyl Phosphate, 1,2 ml in AMP buffer. Preservative: 
Sodium Azide. 
Mode 1 Calibrator 
Mode 1 Calibrator: Mode 1 Calibrator in human serum, nonreactive for 
HBsAg, HIV-1Ag, anti-HCV, and anti-HIV-2.Concentration:0 nm/ml. 
Preservative: Sodium Azide 
Calibrators: 
Digoxin Calibrators are prepared in human serum, nonreactive for HBsAg , 
HIV-1 Ag, anti-HCV,and anti-HIV-1/HIV-2 at the following  
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Concentration:              Bottle   Digoxin Concentration (nm/ml) 
                                   Cal A                        0.0 
                                   Cal B                        0.5  
                                   Cal C                        1.0 
                                   Cal D                        2.0 
                                   Cal E                         3.0 
                                   Cal F                         4.0 
Preservative : Sodium Azide. 
Controls: 
Digoxin Controls were prepared in human serum, nonreactive for HBsAg, 
HIV-1Ag, anti-HCV, and anti-HIV-1/HIV-2 to yield the following 
concentration ranges: 
       Bottle              Digoxin Concentration (nm / ml)     Range ( nm / ml) 
      Control L                   0.9                                                         0.6-1.2 
      Control M                   1.9                                                        1.5-2.3 
      Control H                    3.2                                                        2.5-3.9 
Preservative: Sodium Azide. 
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Sample volume: 150 µ L   of specimen was the minimum volume required 
to perform the assay. 
Procedure: 
* Calibration: 
 For IMx Digoxin Calibration, run all IMx assays –specific calibrator levels 
were run in duplicate in the first carousel positions, followed by all levels of 
controls. 
Once the assay calibration was accepted and stored, all subsequent runs 
were tested in MODE 1 with MODE 1Calibrator in position 1 of the 
carousel. 
* Quality Control: 
Abbot Digoxin Control values should be within the range specified in the 
reagents. If a control value is out of its specified range, the test results 
considered invalid and assay recalibration may be indicated. 
The minimum control requirement for an IMx Digoxin MODE 1Assay is 
one control on each carousel.  
Calculations:  
 Concentration in nmol / L = Concentration in ng / ml × 1.28 
2.2.2. Determination of Serum Creatinine level 
Serum creatinine was determined by photometric colorimetric test for 
kinetic measurements (without deproteinisation.), using Creatinine Human 
Kit (132, 133). 
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Principle: 
Creatinine forms in alkaline solution an orange-red colored complex with 
picric acid. The absorbance of this complex is proportional to the creatinine 
concentration in the sample (132, 133). 
Creatinine + Picric acid ? Creatinine – picrate complex 
Normal value of serum creatinine level: 
 0.6-1.1 mg / dl (Men), 
 0.5-0.9 mg / dl (women) (134, 135). 
Reagents:    
 
R1 (Pic) 
 
Picric acid 
 
26 mmol/l 
NaOH Sodium Hydroxide 1.6 mol/l 
STD Creatinine 2 mg/dl 
 
Dilute sodium hydroxide (NaOH ) with distilled water in the ratio of 1: 4 
Store the solution in a plastic bottle . 
Mix pic and diluted sodium hydroxide   (NaOH) for the working reagent in 
the ratio 1:1. 
The (STD) was ready for use. 
Procedure: 
1- Assay conditions: 
      Wave length… …… Hg   492 nm,(490 -510) nm. 
      Corvette:…………   1cm  
      Temperature:   ……    25ºC.  
      Optical path: … . …1cm 
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 2-   Measurement:          against air (increasing absorbance) 
3- The following were pipetted and mixed into a cuvette:           
 
 
 
 
 
Calculations: 
1- Serum/Plasma 
2- C =  2.0  ×   ∆A Sample ÷ ∆A (STD)  =          (mg/dl 
3-  C =  176.8 ×  ∆ A Sample ÷ ∆A (STD) =       (µmol/l) 
2.3 Performing Liver Function Tests 
2.3.1 Determination of Serum Total and Direct Bilirubin Level 
 Serum direct, and total blirubin, were determinate by dimethylsulfoxide  
(DMSO),colorimetric test , using bilirubin Spin react Kit (136 ). 
Principle: 
Bilirubin was converted to colored azobilirubin by diazotized sulfanilic acid 
and measured photometricacally .Of the two  fractions presented in serum, 
bilirubin glucuronide  and  free bilirubin loosely bounded  to albumin , only 
the former  reacted directly in aqueous solution (direct bilirubin), while free 
Pipette into cuvettes Semi Micro 
Sample / STD 100 (µl) 
Working reagent 1000 µ(   l) 
Mix and start the stopwatch. After 30 sec. read  the 
absorbance A1,  read after 2 min exactly  the absorbance A2  
was  read  .A2-A1= ∆A sample or ∆A (STD) 
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bilirubin required solubilization with dimethylsulfoxide  (DMSO) to react  
(indirect bilirubin),in the determination of indirect bilirubin the direct is 
also determined ,the results correspond to total bilirubin. The intensity of 
the color formed was proportional to the bilirubin concentration in the 
sample (136, 137) 
Normal value of serum bilirubin level: (136).   
 Total 
bilirubin ……..Up to 1.10 mg/dl                          
 Direct bilirubin ……Up to 0.25 mg/dl  
Procedure: 
1- Assay conditions: 
R1(D): Sulfanilic acid 
Hydrocloric acid 
(Hcl) 
30 mmol/l 
150 mmol/l 
 
R2(T) : Sulfanilic acid 
Hydrocloric acid 
(Hcl) 
Dimethilsulfoxide 
(DMSO) 
30 mmol/l 
50 mmol/l 
7 mol/l 
 
R3     : Sodium nitrite 29 mmol/l 
 
Optional : Bilirubin Calibrator 20 mg/dl 
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     Wavelength……..555nm, (530-580) nm 
      Corvette:…………1cm light path 
       Temperature…....15-25ºC 
1-   First the instrument was adjusted to zero with distilled water. 
2-The following were pipetted and mixed into a cuvette:     
 
4-Mix and incubate exactly for 5 minutes at 15-25ºC before reading of the 
absorbance (A) was taken. 
5- The absorbance of each sample was measured against blank at 555nm in 
Stat Fax 1904 spectrophotometer. 
Calculations: 
*With Calibrator: 
((A) Sample – Sample Blank) ÷ ((A) Calibrator - (A) Calibrator Blank) 
×Conc. Calibration =      mg/dl bilirubin  
*With Factor: 
(A) Sample - (A) Sample Blank  ×Factor =     mg/dl bilirubin in the sample. 
Factor: Concentration of Calibrator ÷ (A) Calibrator – (A) Calibrator Blank 
     Blank    Total B.     Blank   Direct B. 
R1(D) (ml)      ----     -----      1.5       1.5 
R2(T) (ml)      1.5      1.5        ---        --- 
R3    (µL)          ---      50       ----         50 
Sample /Calibrator(µL)         100       100      100         100 
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Theoretical factor: Bilirubin (T) =19. 1   
                                     Bilirubin (D) =14 
2.3.2 Determination of Serum Alkaline Phosphtase level (ALP) 
Serum Alkaline Phosphatase (ALP) activity was determinate by 
colorimetric test, using Alkaline Phosphatase Randox Kit (138). 
Principle: 
Alkaline phosphatase (ALP) activity was determined according to the 
following reaction:                             
                                                              ALP 
The p-nitrophenylphosphate + H2O ?  phosphate + p-nitro phenol  
Normal value of serum alkaline phosphatase level: 
  At 37ºC...98-279 U/I 
Reagents: 
      Buffer  :  
 
Diethanolamine buffer 
MgCl2 
1 mol / l , PH 9,8 
0.5 mmol/l 
      Substrate: 
 
p-
nitrophenylphosphate 
10 mmol / l 
 
Procedure: 
Wavelength:      Hg 405 nm 
 Corvette:       1 cm light path   
 Temperature:       37ºC    
 Measurement:      against air 
The following were pipetted and mixed into a corvette:    Semi Micro                                 
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Sample                                                                                      0.02 ml 
Reagent (37º C)                                                                         1.00 ml 
It was mixed and initial absorbance was read it then started timer 
simultaneously. After 1,2 and 3 min read it again. 
The absorbance of each sample was measured against blank at 405 nm in 
Stat Fax 1904 spectrophotometer. 
Calculations: 
To calculate the ALP activity I used the following formula:  
U/I   = 2760 × ∆ A                 405 nm/min       Simi-Micro. 
2.3.3 Determination of Serum Glutamic Oxaloacetic 
Transferase (SGOT) Activity 
 
Serum glutamic oxaloacetic transferase (SGOT) activity was determined by 
U.V. test, using Glutamic Oxaloacetic Transferase Activity Randox Kit 
(139). 
Principle: 
The principle is based on the following reaction: 
                                                 AST 
ά oxoglutarate +  L-aspartate   ?    L-glutamate +    oxaloacetate  
                                             MDH 
oxaloacetate + NADH +H + ?      L - malate +     NAD+ 
The rate of NADH consumption was determined photometrically and was 
direct proportional to the SGOT (AST) activity in the sample. 
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Normal value of serum glutamic oxaloacetic transferase level: 
             At 37 º C…..up to 37 U/I (Men) …...up to 31 U/I(women) 
Reagents: 
 
Procedure: 
Wavelength:   340 nm,  (Hg 334 nm or Hg  365nm)                                  
Corvette:    1 cm light path   
 Temperature:    37ºC    
 Measurement:   against air 
The following were pipetted and mixed into a cuvette:   Semi Micro  
 
1-Buffer / Substrate 
 
2-Enzyme/Coenzyme / ά -
oxoglutarate 
 
 
Phosphate buffer (PH 7.4) 
     L-aspartate 
MDH 
LD 
NADH 
ά –oxoglutarate 
 
 
80 mmol / l 
    200 mmol/ l 
≥0.6 U / ml 
≥ 1.2 U / ml 
0.18 mmol / l 
   12 mmol / l 
Sample                                                               0.2 ml 
Enzyme/Coenzyme/ ά -oxoglutarate, (37º C )                 1.0  ml   
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It was mixed, and initial absorbance was read after 1 min then timer was 
started. After 1, 2 and 3 min the reading were taken.  
Calculations: 
To calculate the AST activity we used the following formulae: 
U/I = 952 ×∆A             Hg 340 nm/min 
U/I =971 ×∆A              Hg 334 nm/min 
U/I =1765 × ∆A            Hg 365 nm/min   
2.3.4 Determination of Serum Glutamic Pyruvic Transferase  
(GPT)(ALT) Activity 
Serum glutamic pyruvic transferase  (SGPT) a activity was determined by 
NADH Kinetic U.V. test, using Glutamic Pyruvic Transferase  Activity 
Spin react Kit (140). 
Principle: 
Analine aminotransferase (ALT) Glutamate pyruvate transaminase (SGPT) 
catalyses the reversible transfer of an amino group from alanine to – ά keto-
glutamate forming glutamate and piruvate.The piruvate produced is reduced 
to lactate by lactate dehydrogenises (LDH) and NADH: 
                                         ALT 
Alanine + ά ketoglutarate ? tamate +Piruvate 
                                                   LDH 
Piruvate +NADH + H+ ? Lactate +NAD+ 
The rate of decrease in concentration of ALT present in the sample (141) 
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Normal value of serum glutamic pyruvic transferase level: 
  At 37C…..up to 40 U/I (Men). …...up to 32 U/I (women) (141,142). 
Reagents: 
 
R1(Buffer) 
 
 
 
TRIS pH 7.8 
 L-Alanine 
 
100 mmol/l 
500 mmol/l 
R2 (Substrate) 
 
 
 
 
NADH 
Lactate dehydrogenase 
(LDH) 
ά -Ketoglutarate 
 
0.18 mmol/l 
1200 U/L  
 
15 mmol/l 
 
    
Procedure 
     1- Assay conditions: 
     Wavelength  340 nm. 
     Corvette:   1cm light path 
     Temperature  37ºC  
2-   First the instrument was adjusted to zero with distilled water or air 
3- The following were pipetted and mixed into a cuvette:     
WR (dissolve one tablet of R2 in one vial of R1)           1 ml 
Sample                                                                            100 µ  L 
4- It was mixed, and incubated for 1 minute. 
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5- Initial absorbance (A) of the sample was read it, started the stopwatch 
and read it absorbances at 1-minute intervals thereafter for 3 minutes. 
6-Calculateed the difference between absorbance's and the average 
absorbance differences per minute (∆ A / min). 
7- The blank absorbance (A) at 340 nm<1.00, in Stat Fax 1904 
spectrophotometer. 
Calculations:  
∆ A/min × 1750         U/L of ALT 
2.3.5 Determination of Serum Albumin Level 
 Serum albumin was determinate by bromcresol green colorimetric test, 
using Albumin Spin react Kit (143). 
Principle: 
Albumin in the presence of bromcresol green at a slightly acid pH produces 
a color change of the indicator from yellow–green to green-blue. The 
intensity of the color formed was proportional to the albumin concentration 
in the sample (143,144,145,146). 
Normal value of serum albumin level: 3.5 to 5.0 g /dl (143). 
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Reagents: 
 
R 
 
Bromcresol green pH 4.2 
 
 
50 mmol/l 
 
Albumin Cal 
 
Albumin aqueous primary 
standard 
 
5g/dl 
 
 
Procedure: 
1- Assay conditions: 
    Wavelength……..630 nm. (600-650) nm. 
    Corvette…1cm light path 
     Temperature…...15-25ºC  
2-   First, the instrument was adjusted to zero with distilled water. 
3- The following were pipetted and mixed into a cuvette:          
 
 
 
 
4- It was mixed, and incubated for 10 mint at room temperature (15-25ºC). 
5- The absorbance (A) of the samples was read and   standardized, against 
the blank at 630nm in Stat Fax 1904 spectrophotometer. 
     Blank   Standard. Sample 
R (ml) 1.0 1.0 1.0 
Standard (µL) ---- 5 --- 
Sample  (µL)    --- --- 5 
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6-The color was stable 1 hour at room temperature. 
Calculations: 
((A) Sample ÷ (A) Standard) × 5 (Standard conc.)  =      g/dL albumin in the 
sample 
 
Conversion factor: g/dl   × 144.9 = µ mol/L 
2.3.6 Determination of Serum of Total Protein Level 
Serum total protein was determined by biuret colorimetric test, using Total 
Protein Spin react Kit (147) 
Principle: 
Proteins give an intensive violet-blue complex with copper salts in an 
alkaline medium. Iodide was included as an antioxidant. 
The intensity of the color formed is proportional to the total protein 
concentration in the sample (147,148). 
 
Normal value of serum total protein level:  Adults: 6.6-8.3 g / dl (147). 
 
 
 
 
 
 
56 
 
Reagents: 
 
R 
Biuret 
Sodium potassium tartrate 
Sodium iodide 
Potassium iodide 
Copper (11) sulphate 
 
15 mmol/l 
100 mmol/l 
5 mmol /l 
5 mmol/l 
 
 
Total protein Cal 
 
 
Bovine albumin  primary 
standard 
 
7  g/dl 
 
 
 
Procedure: 
1- Assay conditions: 
     Wavelength……..540nm, (530-550) nm. 
      Optical path:……1cm light path 
      Temperature…..37ºC.15-25ºC  
2-   First, the instrument was adjusted to zero with distilled water. 
3- The following were pipetted and mixed into a cuvette:               
 
 
 
 
 Blank Standard. Sample 
R (ml) 1.0 1.0 1.0 
Standard (µL) ---- 2 5 --- 
Sample  (µL) --- --- 2 5 
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4- It was mixed, and incubated for 5 min. at 37ºC or 10 min. at room 
temperature (15-25ºC). 
5- The absorbance (A) of the samples was read it and   standard, against the 
blank at 630 nm in Stat Fax 1904 spectrophotometer. 
6-The color was stable for at least 30 minutes. 
Calculations: 
((A) Sample ÷    (A) Standerd)   × 7 Standerd conc. =   g / dl of total protein 
in the sample 
2.4 Determining Electrolyte Level Test 
2.4.1 Determination of Serum Calcium Level 
 Serum calcium was determined by photometric test, using Calcium Human 
Kit (149). 
Principle: 
Calcium ions react with o-cresolphthalein-complex one in an alkaline 
medium form a purple colored complex. The absorbance of this complex is 
proportional to the calcium concentration in the sample (149,150). 
Normal value of Serum calcium level:  8.1-10.4 mg / dl  
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Reagents: 
Buffer Solution(  BUF) 
 
Color Reagent (RGT) 
 
Stander (STD) 
Lysine buffer (pH 11.1) 
Sodium azide 
 
8-Hydroxyquinoline 
o-Cresolph thalein complexone 
Hydrochloric acid 
 
Calcium (11) 
Sodium azide 
 
0.2  mol /l 
0.095 % 
 
14 mmol/l 
0.1 mmol/l 
40 mmol/l 
 
8mg/dl or2 mmol /l 
0.095% 
 
Procedure: 
1- Assay conditions: 
     Wavelength……..       570 nm, Hg 578nm. 
     Optical path:…………1cm  
      Temperature…              20-25ºC.  
2- Measurement:       against reagent blank. Only one reagent blank per 
seines is required. 
3- The following were pipetted and mixed into a cuvette:   Semi Micro                               
Working reagent add (RGT) to (BUF) in equal volumes as required and  
Allowed to stand for 10 minutes at room temperature before used. 
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Calculations: 
C = 8    ×   ∆A Sample ÷∆A (STD)    =      (mg/dl) 
Or   C   = 2      × ∆ A Sample ÷ ∆A (STD) = (mmol/l)                       
2.4.2 Determination of Serum Potassium Level: 
Serum potassium was determined by tetraphenylboron (TPB-Na) method, 
u s i n g  P o t a s s i u m  S p i n  r e a c t  K i t  ( 1 5 1 ) . 
Principle: 
Potassium ions in a protein–free alkaline medium react with sodium 
tetraphenylboron to produce a finely dispersed turbid suspension of 
potassium tetraphenylboron. The turbidity produced is proportional to the 
potassium concentration and read photo metrically. 
Normal value of serum potassium level:  3.60-5.50 mmol/L 
 
 
Pipette into corvettes 
 
Reagent 
blank 
Sample or 
(STD) 
Sample / STD ------ 
 
20 (µl) 
 
Working reagent 1000 (µl) 1000 (  µ l) 
 
Mix and measure the absorbance of sample ( ∆ A sample) 
and standard ( ∆A STD)  against the reagent blank within 5 to 50 
minutes.  
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Reagents: 
 
R.1(TPB-Na) 
 
 
R.2 NaOH 
 
K-p CAL 
Tri chloro acetic acid (TCA) 
Sodium tetraphenylboron (TPB-Na) 
 
Sodium hydroxide 
 
 
Sodium aqueous primary stander 
0.3 mol/l              
0.2 mol/l 
 
2.0 mol/l 
 
 
5.0 mmol/l 
Procedure: 
1- Assay conditions: 
     Wavelength……..578 nm. 
      Corvette:…………1cm. light path  
      Temperature…….37ºC /15-25ºC.  
2-   First, the instrument was adjusted to zero with distilled water. 
3- The following were pipetted and mixed into a cuvette:     Semi Micro      
Working reagent (Mix equal volumes of R.1 (TPB-Na) and R.2 
NaOH were allowed to stand for 15 -30 minutes prior to use. 
 
 
 
4-It was mixed carefully. 
5-Centrifuged at high speed for 5-10 min. 
6- Separated the clear supernatant and pipetted on another cuvette:  
   
Sample( µL) 50 
Precipitating ( µ  L) 500 
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7- To produce a homogeneous turbidity, the standard or the clear 
supernatant should be added to the center of the surface of the working 
reagent in the corvette. Each corvette was mixed carefully before 
proceeding to the next sample. Mixed and allowed to stand for 5 min. 
8-The absorbance (A) of standard and samples against working reagent 
blank were read between 5 and 30 minutes. 
Calculations: 
(A Sample ÷A (STD))   ×5.00  (Standard conc.) =       mmol/L potassium in 
the sample  
2.4.3 Determination of Serum Sodium Level: 
Using the ISE model of the Roche / Hitachi systems which are intended for 
the quantitative determination of sodium serum using ion – selective 
electrodes  
Principle: 
An Ion-Selective Electrode (ISE) makes use of the unique properties of 
certain membrane materials to develop an electrical potential (electromotive 
force, EMF) for the measure regents of ions in solution. 
 Stander Sample 
Working reagent (ml) 1.0 1.0 
Stander (µL   )  100 ---- 
Supernatant ( µ  L) ---- 100 
 
62 
 
The electrode has a selective membrane in contact with both the test 
solution and an internal filling solution .The internal filling solution 
contains the test ion at a fixed concentration. Because of the particular 
nature of the membrane, the test ions will closely associate with the 
membrane on each side. The membrane EMF is determined by difference in 
concentration of the test ion in the test solution and the internal filling 
solution .The EMF develops according to the Nernest equation for a 
specific ion in solution:  
(1) E = E0 + RT/nF .(f.Ct) / (f.Ci) 
Where:  
E =   electrode EMF 
E0 = standard EMF  
R = constant 
T = temperature 
n = charge of the ion  
F = Faraday s constant 
In = natural logarithm (base e) 
F =   activity coefficient 
Ct = ion concentration in test solution 
Ci = ion concentration in internal solution  
For the sodium, which all carry a sing ale charge, R,T,n,and F were 
combined into a sign ale value representing the slope sample was diluted 
1:31 , the ionic strength and therefore the activity coefficients were 
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essentially constant . (On the Roche / Hitachi 902 ISE Module the sample is 
diluted 1:50.) 
The concentration of the test ion in the internal filling solution was also 
constant. These constants might be combined into the E0 term. The value of 
E0 was also specific for the type of reference electrode used. Equation (1) 
could hence be rewritten to reflect these conditions: 
(2) E =E0 + S.In (Ct) 
The complete measurement system for a particular ion included the ISE, a 
reference electrode and electronic circuited to measure and process the 
EMF to give the test ion concentration. 
The sodium electrode was based on ion exchange. 
Normal value of serum sodium level: Adults 136-145 mmol/l 
Reagents: 
ISE calibrators S1, S2 and optional S3     
S1: ISE Stander low                               120 mmol/l Na 
S2: ISE Stander High                            160 mmol/l Na 
S3: ISE Compensator 
Assigned values: see value sheet accompanying package insert                 
Auxiliary reagents: 
ISE Reverence Electrolyte                          1 mol/l potassium chloride  
ISE Diluents (ready for use)                    20 mmol/l boric acid                
                                                                       50 mmol/l Bis-Tris buffer 
Preservative        Or       
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Ise Diluents (concentrate)               approximate concentration after 
reconstitution:                                     65 mmol/l boric acid      
Preservative 
ISE Internal Standard                         20 mmol/l boric acid    
(Ready for use)                                    50 mmol/l Bis-Tris buffer 
                                                            3.23 mmol/l sodium chloride 
                                                                1.29 mmol/l sodium bi carbonate 
                                                           0.16mmol/l  
                                                           Potassium dihydrogenphosphate                                  
ISE Internal Standard (concentrate) 
Approximate concentration                65 mmol/l boric acid 
After reconstitution:                           3.23 sodium chloride 
                                                               1.29 mmol/l sodium bi carbonate 
                                                           0.16 mmol/l Potassium                                                 
                                                           Dihydro genphosphate                                             
Preservative 
ISE Cleaning Solution                      Sodium hydroxide solution, 12%       
Or Sodium hypochlorite solution < 2% active Cl4N NaOH / System 
Cleaning Solution 
 Sodium hydroxide solution, 16% 
Preparation of the concentrated reagents ISE Diluents and ISE Internal 
Standard 
To prepare the working solution, added  1800 ml of sterile distilled or 
demonized water to each 2000 ml bottle ) .Prepared smaller bottles 
according to the instructions on the label. Mix thoroughly by inversion. 
Electrodes         Sodium    Cat.No.10825468 
                       Reference Cat.No.10855782 (for 7- series analyzers only)                            
                                    Na   Slope ranges:  50-68 mV/ dec 
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Procedure: 
Assay: Refer to the Operator. Manual of the analyzer. 
Calibration: The calibration requires the use of high and low standard 
solutions (S1, S2) to determine the slope factor. Use optionally a serum-
based calibrator/compensator S3 as reference to adjust the ISE calibration 
to other systems and also to compensate possible pollution effects. An 
internal standard is measured during calibration and between each sample 
to correct the calibration for system drift. 
Refer to the Operators Manual of analyzer for detailed calibration 
instruction 
Quality Control of Na+ managements: 
Each laboratory should establish guidelines for quality control with two 
levels. 
Serum control: Precinorm U/Precipath U 
Referring to appropriate value sheets/package inserted for additional 
information. 
Quality Controls should be performed daily and after every additional 
calibration each laboratory should establish guidelines for corrective action 
to be taken if controls do not recover within the specified limits. 
Pipe ting parameters: For the Roche/Hitachi and Modular analyzers, a sing 
ale 15 µL   sample is taken for sodium measurement 
3. Statistical Analysis 
Statistical analysis of data was performed using SPSS software package 
Inc, Chicago, IL, Version 11, 0, 2002. The results were expressed as means 
± standard error (SE). Paired T-test was used to assess the null hypothesis  
The level of the significance adopted was as follows: 
* P-value < 0.05         **      P-value < 0.01          ***      P-value <0.001 
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RESULTS 
 
Results of Clarithromycin, Roxithromycin or Azithromycin in 
the Patients under Digoxin Treatment 
1. Symptoms That Observed After New Macrolides Therapy 
Table (2 ) shows the highest percentage of symptoms that observed after 
oral administration of clarithromycin in a dose 500 mg tablet twice a day 
for 7 days in the patients under digoxin therapy is nausea , 85%.  
Table (2) shows the highest percentage of symptoms that observed after 
oral administration of roxithromycin in a dose 300 mg tablet once a day for 
5 days in the patients under digoxin therapy is nausea, 80 %. 
Table (2) shows the highest percentage of symptoms that observed after 
oral administration of azithromycin in a dose 500 mg capsule once a day 
for 3 days in the patients under digoxin therapy is nausea, 25%. 
 
 
 
 
 
68 
 
 
Table (2 ): Symptoms observed after oral administration of clarithromycin  
,roxithromycin or azithromycin in the patients under digoxin therapy . 
      
 
 
 
 
 
 
Symptoms 
 
  
         Frequencies of symptoms 
 
 
 
                             Percentage 
                                    %     
clarithromycin roxithromyin azithromycin clarithromycin roxithromyin azithromycin 
Nausea  
 
34 32 10 85% 80 % 25 % 
Vomiting 32 31 7 80% 77.5 % 17.5 % 
Headache  20 8 1 50 % 20% 2.5 % 
Diarrhea  3 0 0 7.5% 0 0 
Dizziness 10 2 2 25% 5 % 5 % 
Weakness 8 30 4 20 % 75 % 10 % 
Anorexia  5 3 3 12.5 % 7.5 % 7.5  % 
Fatigue  29 12 3 72.5 % 30 % 7.5  % 
Visual 
symptom 
0 0 0 0 0 0 
Abdominal   
    pain  
7 4 4 17.5  % 10% 10 % 
Psychic 
complaints  
1 0 1 2.5  % 0 2.5  % 
69 
 
 
2. Effects of New Macrolides on Serum Digoxin Level 
2.1 Effect of Clarithromycin on Serum Digoxin Level 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days significantly increased serum digoxin level ( 1.975±  0.145to 
3.268 ± 0.115) ng/ml, in the patients under digoxin therapy. The results 
presented in Table (3) and Figure (7) 
 2.2 Effect of Roxithromycin on Serum Digoxin Level 
An oral administration of roxithromycin in a dose of 300 mg  tablet once a 
day for 5 days significantly increased serum digoxin level (1.75 ± 0.114to 
3.177± 0.112) ng/ml in the patients under digoxin therapy. The results 
presented in Table (3) and Figure (7). 
2.3 Effect of Azithromycin on Serum Digoxin Level 
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days significantly increased serum digoxin level (1.407± 0.115 to 
2.581 ± 0.093 ) ng/ml in the patients under digoxin therapy. The results 
presented in Table (3) and Figure (7). 
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Table (3 ): Serum digoxin level before & after  oral administration of clarithromycin  
,roxithromycin or azithromycin in the patients under digoxin therapy ,(M ±  SE , n =40). 
Case 
No. 
Serum  digoxin 
(ng/ml),after clarithromycin 
therapy. 
Serum digoxin(ng/ml), after  
roxithromycin therapy. 
Serum digoxin (ng/ml),after 
azithromycin therapy. 
Before After Before After Before After 
1 2.43 3.38 1.45 1.93 3.1 3.8 
2 2.15 4.0 0.89 2.6 2.2 3.2 
3 2.48 2.4 1.8 2.8 2.3 3.9 
4 2.6 3.5 1.3 2.8 1.2 3.9 
5 0.39 3.7 1.91 2.25 2.2 3.6 
6 0.3 0.9 0.39 3.0 1.5 2.44 
7 1.43 2.96 2.7 2.5 2.1 3.1 
8 2.9 3.99 0.54 2.66 2.2 3.35 
9 3.6 3.32 1.7 2.27 0.54 1.9 
10 3.8 3.9 2.0 2.62 2.1 4.0 
11 1.1 3.7 1.6 2.9 1.7 2.2 
12 0.53 4.0 2.5 3.1 1.9 2.9 
13 2.1 2.64 0.44 2.7 2.43 3.38 
14 1.6 3.3 1.76 3.2 2.15 4.0 
15 2.3 3.5 2.4 3.0 2.6  3.56 
16 0.61 2.9 1.6 2.0 0.89 4.09 
17 2.3 3.1 2.48 2.41 2.1 3.3 
18 3.1 3.81 0.39 3.76 1.61 3.9 
19 2.8 3.9 0.33 2.4 2.32 2.99 
20 3.0 3.8 1.43 2.96 0.61 3.1 
21 2.2 3.2 2.6 4.3 2.3 3.81 
22 2.3 3.9 1.67 3.32 3.1 3.9 
23 3.1 3.9 1.6 3.9 2.8 3.9 
24 1.88 2.87 1.1 3.7 0.34 1.8 
25 1.98 3.4 0.53 2.64 0.39 1.8 
26 2.6 3.8 1.9 2.3 1.7 3.9 
27 0.77 1.95 2.1 2.3 2.2 3.3 
28 1.99 2.49 0.9 1.9 1.9 3.3 
29 2.5 3.6 1.7 2.0 2.0 3.9 
30 1.0 3.0 1.5 2.1 0.9 2.99 
31 2.7 4.1 2.0 2.4 1.7 3.5 
32 1.77 2.9 1.52 1.41 1.66 2.9 
33 0.92 2.7 0.23 2.3 2.4 3.3 
34 0.65 2.9 0.27 2.0 1.8 3.0 
35 2.1 3.9 1.15 2.4 1.5 2.2 
36 1.6 3.1 1.48 1.99 1.1 2.5 
37 2,98 3.99 1.9 1.71 0.9 1.99 
38 0.34 1.58 0.98 2.4 0.59 2.0 
39 1.9 2.55 0.73 2.45 0.98 2.5 
40 2.6 3.9 0.44 2.2 1.99 3.99 
Mean 1.975 3.268*** 1.750 3.177*** 1.407 2.581*** 
SEM 0.145 0.115 0.114 0.112 0.115 0.093 
P-
Value 
.000 .000 
 
.000 
 
*significant difference as compared with serum digoxin  levels after new macrolides therapy , at P<0.001 . 
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Fig. (7):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum digoxin leve                    
(M ±  SE ,   n =40). 
 
*** significant difference as compared with serum digoxin  level after new 
macrolides therapy, at P<0.001 . 
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3. Effects of New Macrolides on Serum Creatinine Level 
3.1 Effect of Clarithromycin on Serum Creatinine Level 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days significantly increased serum creatinine level (1.150± 
0.0865 to 1.900 ± 0.178) mg/dl in the patients under digoxin therapy. The 
results presented in Table (4) and Figure (8).  
 3.2 Effect of Roxithromycin on Serum Creatinine Level 
An oral administration of roxithromycin in a dose of 300 mg tablet once a 
day for 5 days significantly increased serum creatinine level (1.152 ± 
 0.0 67 to 1.656 ± 0.056 ) mg/dl in the patients under digoxin therapy. The 
results presented in Table (4) and Figure (8).  
3.3 Effect of Azithromycin on Serum Creatinine Level 
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days significantly increased serum creatinine level (1.2 ± 0.063to  
2.00 ± 0.118 ) ) mg/dl in the patients under digoxin therapy. The results 
presented in Table (4) and Figure (8). 
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Table (4 ): Serum creatinine  levels  before and after oral administration of clarithromycin  
,roxithromycin or azithromycin in the patients under digoxin therapy ,(M ± SE , n =40) 
 
Case 
No. 
Serum  creatinin(mg/dl),after 
clarithromycin therapy. 
Serum creatinin (mg/dl),, after  
roxithromycin therapy. 
Serum creatinin (mg/dl), after azithromycin 
therapy. 
Before After Before After Before After 
1 2.0 3.3 2.9 1.15 1.0 1.6 
2 1.1 2.5 1.8 0.62 0.5 1.4 
3 2.25 3.56 2.8 1.7 1.1 2.3 
4 1.08 1.34 3.4 0.88 0.6 1.12 
5 1.3 1.3 1.8 1.1 1.1 1.99 
6 0.5 1.08 1.3 1.14 1.14 2.02 
7 0.9 1.23 1.8 1.9 1.85 1.9 
8 2.49 3.3 1.3 0.8 0.8 1.7 
9 1.1 4.7 3.65 1.2 1.2 2.0 
10 2.35 4.77 1.3 1.25 1.25 1.66 
11 1.08 1.34 2.0 1.1 1.5 1.19 
12 0.6 1.56 1.3 0.6 0.6 1.5 
13 1.05 1.46 3.4 1.3 1.3 1.99 
14 0.92 1.48 1.8 1.4 1.86 1.8 
15 0.6 1.48 1.3 1.8 1.8 1.62 
16 0.8 1.36 1.6 1.3 1.3 2.57 
17 1.2 1.07 1.14 1.7 1.7 1.96 
18 1.5 1.05 1.9 0.91 0.91 1.27 
19 0.7 1.81 0.99 0.64 0.64 1.81 
20 1.0 1.0 1.14 1.3 1.3 1.0 
21 0.7 1.28 2.4 4.0 0.8 1.7 
22 0.6 1.03 1.8 1.51 1.51 1.91 
23 0.9 3.0 1.98 1.2 1.2 1.69 
24 2.15 4.5 1.7 1.55 1.76 1.9 
25 0.54 1.5 2.4 0.69 0.59 1.5 
26 1.08 1.04 1.14 0.75 0.4 1.3 
27 0.6 1.26 1.9 1.66 1.4 1.82 
28 1.05 1.15 2.2 1.9 0.9 1.73 
29 0.92 1.19 2.2 1.45 0.65 1.48 
30 0.6 1.7 1.8 1.87 1.87 1.9 
31 0.8 1.06 1.1 1.8 1.1 1.5 
32 0.45 1.37 1.5 2.7 1.5 1.32 
33 1.5 1.35 0.88 2.7 0.88 1.96 
34 0.56 1.81 0.87 3.2 0.87 1.1 
35 1.73 1.5 1.43 1.8 1.43 1.7 
36 1.48 2.2 0.9 2.5 0.9 1.6 
37 1.9 4.5 1.12 0.8 1.12 1.87 
38 1.5 1.55 1.88 2.2 1.9 1.88 
39 1.32 1.45 0.66 1.8 0.66 0.89 
40 1.1 0.9 0.76 1.33 1.2 1.1 
Mean 1.15 1.90*** 1.20 2.00*** 1.152 1.656*** 
SEM 0.865 0.178 0.633 0.118 0.067 0.056 
P-
Value 
.000 .000 .000 
*significant difference as compared with serum creatinine levels after new macrolides therapy, at P<0.001. 
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Fig. (8):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum creatinine level 
(M ±  SE , n =40). 
 
 
 
 
*** significant difference as compared with serum creatinine  level after 
new macrolides therapy, at P<0.001 . 
 
 
 
75 
 
4 Effects of Macrolides on Liver Function Activities         
4.1 Effect of Clarithromycin on Serum Total Bilirubin Level 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days resulted as significantly increased serum total bilirubin level 
(1.026± 0.058 to 1.32 ± 0.062) mg/dl in the patients under digoxin therapy. 
The results presented in Table (5) and Figure (9). 
4.2 Effect of Roxithromycin on Serum Total Bilirubin Level 
An oral administration of roxithromycin in a dose of 300 mg tablet once a 
day for 5 days resulted as no significant effect on  serum total bilirubin 
level (2.627± 0.116 to 2.79 ± 0.143) mg/dl in the patients under digoxin 
therapy. The results presented in Table (5) and Figure (9).  
4.3. Effect of Azithromycin on Serum Total Bilirubin Level 
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days significantly increased serum total bilirubin level (1.825± 
0.1443 to 2.142 ± 0.162) mg/dl in the patients under digoxin therapy. The 
results presented in Table (5) and Figure (9). 
 
 
 
 
76 
 
Table (5 ): Serum total bilirubin levels  before and after oral administration of clarithromycin  ,roxithromycin 
or azithromycin in the patients under digoxin therapy ,(M ± SE , n =40) 
*significant difference as compare dwith serum t.bilirubin levels after clarithromycin & azithromycin therapy, but no significant 
difference as compared with serum t.bilirubin levels after roxithromycin therapy, at P<0.05 . 
Case No.  Serum  t. bilirubin (md/dl),after 
clarithromycin therapy. 
Serumt..bilirubin (mg/dl), after  
roxithromycin therapy. 
Serum  t. bilirubin (md/dl),after 
azithromycin therapy. 
Before  After  Before  After  Before  After 
1  1.01  1.1  3.5  3.1  2.5  3.9 
2  0.3  1.0  2.6  3.9  2.1  1.9 
3  1.4  2.0  0.11  0.62  2.9  2.5 
4  1.1  0.97  2.6  2.3  1.9  3.6 
5  1.2  1.5  3.4  2.0  3.0  1.07 
6  0.7  1.3  3.0  4.0  2.4  1.9 
7  0.9  1.0  2.6  4.0  0.8  1.01 
8  0.9  0.98  2.0  1.8  0.8  1.11 
9  1.1  0.89  3.0  2.6  1.3  1.19 
10  1.4  2.4  1.8  3.5  3.0  1.5 
11  0.8  1.2  3.1  2.9  3.4  1.8 
12  0.8  1.0  2.3  2.0  2.7  0.67 
13  1.2  1.2  3.4  3.1  0.1  2.2 
14  0.2  1.5  2.7  3.0  2.7  1.3 
15  1.4  1.9  2.6  2.2  3.3  2.5 
16  0.97  1.4  2.4  2.7  3.1  4.1 
17  1.07  1.5  3.3  3.1  2.5  3.9 
18  1.5  1.8  2.8  4.1  2.1  1.9 
19  0.3  1.6  2.6  2.2  2.9  2.5 
20  1.1  1.1  3.4  2.7  1.9  3.6 
21  0.9  1.1  3.0  4.1  3.0  2.8 
22  0.7  1.1  3.4  3.0  2.4  2.1 
23  1.5  2.0  2.7  4.0  0.8  2.4 
24  1.0  1.3  0.1  0.6  0.8  2.1 
25  0.8  1.08  2.7  2.4  1.3  1.4 
26  0.8  1.0  3.3  1.9  1.1  2.8 
27  1.3  1.4  3.1  4.1  1.7  2.1 
28  1.1  1.07  2.5  3.9  0.3  1.08 
29  1.7  1.9  2.1  1.9  1.1  1.0 
30  0.3  1.01  2.9  2.5  1.2  2.0 
31  1.1  1.11  1.9  3.6  1.4  3.0 
32  1.2  1.19  3.0  2.8  1.2  3.0 
33  1.4  1.5  2.4  2.1  1.9  4.0 
34  1.2  1.8  3.3  3.0  1.2  0.6 
35  1.9  0.67  2.8  4.2  0.7  2.4 
36  1.2  1.5  2.5  2.1  0.9  1.1 
37  0.7     2.0  2.58  2.81  0.9  0.98 
38  0.9  1.1  2.6  2.3  1.1  0.89 
39  0.9  0.98  2.0  2.0  2.5  3.9 
40  1.1  0.89  3.0  2.6  2.1  1.9 
Mean  1.026  1.326***  2.627  2.793  1.825  2.142* 
SEM  0.058  .0622  0.116  0.143  0.144  0.162 
P‐Value  .000  0.213  0.088 
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Fig. (9):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum t.bilirubin level, 
 (M ±  SE , n =40). 
 
*significant difference as compared with serum t.bilirubin levels after clarithromycin & 
azithromycin therapy, but no significant difference as compared with serum t.bilirubin 
levels after roxithromycin therapy, at P<0.05 . 
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4.4 Effect of Clarithromycin on Serum Direct Bilirubin  Level 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days produced no significant effect on serum direct bilirubin  
level (0.351  ± 0.021 to 0 .312 ± 0.016) mg/dl in the patients under digoxin 
therapy. The results presented in Table (6) and Figure (10). 
4.5 Effect of Roxithromycin on Serum Direct Bilirubin Level  
An oral administration of roxithromycin in a dose of 300 mg capsule once a 
day for 5days  significantly  increased on serum direct bilirubin level 
(0.341  ± 0.0.018 to 0.445  ± 0.053) mg/dl in the patients under digoxin 
therapy. The results presented in Table (6) and Figure (10). 
4.6 Effect of Azithromycin on Serum Direct Bilirubin Level  
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days produced no significant effect on serum direct bilirubin level 
(0.347 ± 0.028 to 0.386  ± 0.042) mg/dl  in the patients under digoxin 
therapy. The results presented in Table (6) and Figure (10). 
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Table (6 ): Serum tdirect bilirubin levels  before and after oral administration of clarithromycin  ,roxithromycin or 
azithromycin  in the patients under digoxin therapy ,(M ± SE , n =40) 
Case No.  Serum d.bilirubin 
(mg/dl), after  
clarithromycin therapy 
Serum d.bilirubin(mg/dl),  
After Roxithromycin 
           therapy 
 
Serum d.bilirubin (mg/dl), after  azithromycin 
therapy. 
Before  After  Before  After  Before  After 
1  0.38  0.5  0.47  0.48  0.41  0.3 
2  0.34  0.1  0.23  0.7  0.37  0.23 
3  0.48  0.39  0.3  1.5  0.31  0.3 
4  0.28  0.33  0.45  0.54  0.3  0.22 
5  0.3  0.4  0.21  0.5  0.23  0.31 
6  0.19  0.13  0.4  1.1  0.16  0.4 
7  0.31  0.4  0.4  0.18  0.18  0.22 
8  0.2  0.54  0.41  0.53  0.13  0.16 
9  0.25  0.5  0.1  0.26  0.3  0.18 
10  0.63  0.6  0.13  0.36  0.6  0.21 
11  0.16  0.13  0.39  0.2  0.2  0.41 
12  0.18  0.3  0.44  0.54  0.37  0.4 
13  0.21  0.6  0.3  0.16  0.31  0.34 
14  0.41  0.2  0.4  1.3  0.28  0.4 
15  0.37  0.4  0.46  0.47  0.44  0.2 
16  0.31  0.34  0.3  0.22  0.22  0.29 
17  0.28  0.4  0.23  0.31  0.35  0.43 
18  0.44  0.2  0.3  0.32  0.22  0.3 
19  0.22  0.29  0.4  0.43  0.31  0.23 
20  0.35  0.43  0.34  0.31  0.3  0.35 
21  0.22  0.3  0.4  0.28  0.4  0.47 
22  0.31  0.23  0.2  0.44  0.22  0.3 
23  0.32  0.3  0.29  0.22  0.55  0.18 
24  0.43  0.4  0.43  0.35  0.18  0.31 
25  0.26  0.22  0.2  0.44  0.55  0.4 
26  0.18  0.55  0.29  0.23  0.23  0.7 
27  0.31  0.18  0.43  0.35  0.23  0.7 
28  0.4  0.55  0.3  0.22  0.3  1.5 
29  0.47  0.5  0.41  0.53  0.54  0.45 
30  0.21  0.3  0.22  0.26  0.5  0.21 
31  0.28  0.3  0.55  0.18  1.1  0.4 
32  0.34  0.44  0.12  0.36  0.18  0.4 
33  0.48  0.3  0.39  0.2  0.53  0.41 
34  0.28  0.2  0.44  0.54  0.26  0.1 
35  0.3  0.39  0.24  0.16  0.36  0.13 
36  0.19  0.33  0.4  1.3  0.2  0.39 
37  0.3  0.4  0.46  0.47  0.54  0.44 
38  0.2  0.3  0.32  0.5  0.16  0.3 
39  0.3  0.5  0.3  0.18  0.4  1.3 
40  0.43  0.2  0.6  0.21  0.46  0.47 
Mean  0.312  0.351  0.341  0.445*  0.347  0.386 
SEM  0.163  0.021  0.018  0.050  0.028  0.042 
P‐Value  0.112  0.053  0.447 
*significant difference as compared with serum d.bilirubin levels after roxithromycin therapy, but no significant difference as 
compared with serum d.bilirubin levels after clarithromycin & azithromycin  therapy, at P<0.05 . 
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Fig. (10):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum d.bilirubin level, 
 (M ±  SE , n =40). 
 
*significant difference as compared with serum d.bilirubin levels after roxithromycin 
therapy, but no significant difference as compared with serum d.bilirubin levels after 
clarithromycin & azithromycin  therapy, at P<0.05 
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4.7 Effect of Clarithromycin on Serum Total Protein Level 
An oral administration of clarithromycin in a dose of 500 mg tablet  twice a 
day for 7 days produced no significant effect on serum total protein level 
(7.269 ± 0.119 to 7.264 ± 0.129) mg/dl in the patients under digoxin 
therapy. The results presented  in Table (7) and Figure (11). 
4.8 Effect of Roxithromycin on Serum Total Protein Level 
An oral administration of roxithromycin in a dose of 300 mg tablet once a 
day for 5days produced no significant effect on serum total protein level 
(6.486±0.0793to 6.559± 0.118)  mg/dl the patients under digoxin therapy. 
The results presented in Table (7) and Figure (11). 
 
4.9 Effect of Azithromycin on Serum Total Protein Level 
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days produced no significant effect on serum total protein level 
(7.088± 0.135 to 7.059 ± 0.134) mg/dl in the patients under digoxin 
therapy. The results presented in Table (7) and Figure (11). 
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                        Table (7 ): Serum total protein levels  before and after oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy ,(M ± SE , n =40) 
Case 
No. 
Serum  total. protien(md/dl),after 
clarithromycin therapy. 
Serum total protien (mg/dl), after 
Roxithromycin therapy. 
 Serum  total protien (md/dl),after azithromycin 
therapy. 
Before After Before After Before After 
1  7.0 7.5 6.1  6.0  8.0  7.9 
2  7.5 6.5 7.3  7.9  6.5  5.9 
3  7.3 7.5 6.2  5.9  8.3  8.0 
4  6.72 6.5 6.9  6.2  8.0  7.8 
5  7.3 7.2 6.8  7.0  6.7  8.0 
6  7.8 7.6 6.2  6.8  8.0  6.4 
7  6.9 6.5 5.6  5.8  7.3  7.0 
8  7.0 6.5 7.2  6.9  8.8  7.7 
9  6.0 5.8 6.1  6.0  7.0  8.0 
10  6.4 7.0 6.7  7.9  7.62  7.59 
11  6.6 6.8 5.7  5.9  8.0  8.3 
12  8.1 5.8 6.8  6.1  6.7  7.9 
13  7.9 6.9 7.4  7.8  5.7  5.9 
14  6.0 6.0 6.1  5.8  6.8  6.1 
15  8.0 7.9 6.0  6.2  7.4  7.8 
16  6.5 5.9 6.47  6.69  6.1  5.8 
17  8.3 8.0 6.3  6.2  6.0  6.2 
18  8.0 7.8 7.1  7.7  6.47  6.69 
19  6.7 8.0 6.4  6.1  6.3  6.2 
20  8.0 6.4 6.7  6.0  7.1  7.7 
21  7.0 8.8 7.0  7.2  6.4 6.1 
22  8.8 7.7 6.5  6.6  6.7 6.0 
23  7.0 8.0 5.8  6.0  7.0 7.2 
24  7.62 7.59 7.0  6.7  6.5 6.6 
25  8.0 8.3 6.3  8.2  5.8 6.0 
26  6.5 7.5 6.5  7.7  7.0 6.7 
27  7.7 8.4 6.0  6.1  7.4 7.3 
28  8.7 7.9 6.6  5.9  8.0 5.9 
29  7.4 7.3 7.6  7.0  6.9 7.0 
30  6.0 7.9 5.9  5.6  6.0 7.9 
31  6.9 7.0 6.2  6.4  8.0 6.8 
32  8.0 5.9 6.27  6.4  8.5 6.7 
33  6.8 8.0 6.0  6.2  7.9 6.9 
34  5.8 6.7 6.4  6.4  7.52 7.9 
35  7.0 6.9 6.1 5.8 6.72 8.9 
36  7.52 7.9 7.4 7.8 8.8 8.0 
37  6.72 8.9 6.4 5.6 7.0 6.9 
38  8.2 6.9 6.1 6.1 6.8 8.0 
39  7.8 7.9 7.0 7.7 6.0 6.7 
40  7.0 3.3 6.3 6.0 5.8 6.0 
Mean  7.269  7.264  6.486  6.559  7.088  7.059 
SEM  0.119  0.129  0.079  0.118  0.135  0.134 
P‐Value  0.976  0.411  0.841 
*No significant difference as compare dwith serum t.protien levels after new macrolides  therapy, , at P<0.05 . 
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Fig. (11):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or in 
the patients under digoxin therapy , on serum t.protien level,( (M ±  SE , n =40). 
 
 
*No significant difference as compared with serum t. protien levels after new 
macrolides  therapy, , at P<0.05 . 
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4.10 Effect of Clarithromycin on Serum Albumin Level 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days produced no significant effect on serum albumin level (5.04 
± 0.264 to 5.067 ± 0.241) mg/dl in the patients under digoxin therapy in 
Table (8) and Figure (12). 
4.11 Effect of Roxithromycin on Serum Albumin Level 
An oral administration of roxithromycin in a dose of 300 mg tablet once a 
day for 5 days significantly decreased serum albumin level (3.762± 0.06 to 
3.48 ± 0.065)  mg/dl in the patients under digoxin therapy. The results 
presented in Table (8) and Figure (12). 
4.12 Effect of Azithromycin on Serum Albumin Level 
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days significantly decreased serum albumin level (4.515 ± 0.228 
to 3.91 ± 0.165) mg/dl in the patients under digoxin therapy. The results 
presented in Table (8) and Figure (12). 
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                          Table (8): Serum albumin levels  before and after oral administration of clarithromycin  ,roxithromycin or azithromycin 
in the patients under digoxin therapy ,(M ± SE , n =40) 
Case 
No. 
Serum albumin 
(mg/dl),after clatihromycin 
therapy. 
Serum  albumin(md/dl),after 
roxithromycin therapy. 
Serum albumin(mg/dl), after  azithromycin 
therapy. 
Before  After  Before  After  Before  After 
1  3.6  3.8  3.9  3.0  3.6  3.3 
2  3.9  4.0  4.5  3.2  3.7  3.5 
3  3.7  3.9  3.5  3.5  4.3  3.0 
4  3.4  4.1  3.5  3.2  3.3  3.3 
5  3.5  3.2  3.6  3.1  3.3  3.0 
6  4.1  4.6  4.2  3.1  3.4  3.0 
7  4.0  3.0  3.3  3.6  4.0  3.0 
8  3.9  4.1  4.0  3.7  3.1  3.4 
9  3.4  3.9  3.8  3.3  3.8  3.5 
10  4.6  3.7  3.7  3.9  4.0  4.5 
11  3.3  4.2  3.6  3.9  3.9  4.1 
12  3.0  4.3  3.4  3.1  3.8  4.1 
13  4.3  3.9  4.6  3.4  3.6  3.3 
14  3.9  3.9  3.5  3.2  4.8  3.6 
15  4.3  3.6  3.8  3.4  3.7  3.4 
16  4.2  4.3  3.79  3.3  4.0  3.0 
17  7.0  4.9  3.9  4.1  3.9  3.5 
18  6.8  3.7  3.8  4.1  3.1  3.4 
19  4.2  7.4  3.6  3.3  3.9  4.1 
20  7.7  3.8  3.7  3.5  3.4  3.9 
21  7.0  3.3  4.3  3.0  4.6  3.7 
22  7.5  4.3  3.3  3.3  3.3  4.2 
23  6.5  4.0  3.3  3.0  3.0  4.3 
24  6.9  3.4  3.4  3.0  4.3  3.9 
25  7.8  8.0  4.0  3.0  3.9  3.9 
26  6.3  6.5  3.1  3.4  4.3  3.6 
27  7.5  7.4  3.8  3.5  4.2  4.3 
28  8.0  5.9  4.0  4.5  7.0  4.9 
29  6.5  7.0  3.9  4.1  6.8  3.7 
30  3.8  7.8  3.8  4.1  4.2  7.4 
31  3.0  6.9  3.6  3.3  7.7  3.8 
32  7.2  5.1  4.8  3.6  7.0  3.3 
33  3.1  6.0  3.7  3.4  7.5  4.3 
34  3.6  6.4  4.0  3.0  6.5  4.0 
35  3.8  6.6  3.9  3.5  6.6  3.4 
36  4.1  4.9  3.1  3.4  7.8  7.5 
37  3.5  7.9  3.8  3.5  6.3  6.5 
38  7.0  5.4  3.1  3.4  4.0  3.0 
39  5.9  7.0  4.0  4.5  3.9  3.5 
40  5.8  6.59  3.9  4.1  3.1  3.4 
Mean  5.040  5.067  3.762 3.487** 4.515 3.912* 
SEM  0.264  0.241  0.060 0.065 0.228 0.165 
P‐
value 
0.936  0.002 0.01 
No significant difference as compared with serumalbumin levels after clarithromycin therapy,but  , significant difference as compared with 
serum albumin levels after roxithromycin & azithromycin  therapy at P<0.05 
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Fig. (12):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum albumin level, 
 (M ±  SE , n =40). 
 
 
No significant difference as compared with serum albumin levels after clarithromycin 
therapy,but  , *significant difference as compared with serum albumin levels after 
roxithromycin & azithromycin  therapy at P<0.05 
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4.13 Effect of Clarithromycin on Serum Globulin Level 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days produced no significant effect on serum globulin level 
(2.229± 0.212 to 2.192 ± 0.208) mg/dl in the patients under digoxin 
therapy. The results presented in Table (9) and Figure (13). 
4.14 Effect of Roxithromycin on Serum Globulin Level 
An oral administration of azithromycin in a dose of 300 mg capsule once a 
day for 5 days significantly increased serum globulin level (2.73 ± 0.086 to 
  3.07 ± 0.136) mg/dl in the patients under digoxin therapy. The results 
presented in Table (9) and Figure (13) 
4.15 Effect of Azithromycin on Serum Globulin Level 
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days significantly increased serum globulin level (2.543 ± 0.22 to 
  3.147 ± 0.198)  mg/dl in the patients under digoxin therapy. The results 
presented in Table (9) and Figure (13). 
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                                             Table (9): Serum globulin levels  before and after oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy ,(M ± SE , n =40) 
Case 
No. 
Serumglobulin.(mg/dl),after 
clarithromycin therapy. 
Serum   globulin (mg/dl), after  
roxithromycin therapy. 
Serum   globulin  (mg/dl),after azithromycin 
therapy 
Before  after  Before  After  Before  After 
1  3.4  3.7  2.2  3.1  4.4  4.6 
2  3.6  2.5  2.8  4.7  2.8  2.4 
3  3.6  3.6  2.7  2.4  4.0  5.0 
4  3.32  2.4  3.4  3.0  4.7  4.5 
5  3.8  4.0  3.2  3.9  3.4  5.0 
6  3.7  3.0  2.0  3.7  4.6  3.4 
7  2.9  3.5  2.3  2.2  3.3  4.0 
8  3.1  2.4  3.2  3.2  5.7  4.3 
9  2.6  1.9  2.3  2.7  3.2  4.5 
10  1.8  3.3  3.0  4.0  3.62  3.09 
11  3.3  2.6  2.1  2.0  4.1  4.2 
12  5.1  1.5  3.4  3.0  2.9  3.8 
13  3.6  3.0  2.8  4.4  2.1  2.6 
14  2.1  2.1  2.6  2.6  2.0  2.5 
15  3.7  4.2  2.8  2.8  3.7  4.4 
16  2.3  1.5  2.68  3.39  2.1  2.8 
17  1.3  3.1  2.4  2.1  2.1  2.7 
18  1.2  4.1  3.3  3.6  3.37  3.29 
19  2.5  0.6  2.8  2.8  2.4  2.1 
20  0.3  2.6  3.0  2.5  3.7  3.8 
21  0.3 3.7 2.7  4.2  1.8  2.4 
22  1.3 3.4 3.2  3.3  3.4  1.8 
23  0.5 4.0 2.5  3.0  4.0  2.9 
24  0.72 4.19 3.6  3.7  2.2  2.7 
25  0.2 0.3 2.3  5.2  1.9  2.1 
26  0.2 1.0 3.4  4.3  2.7  3.1 
27  0.2 1.0 2.2  2.6  3.2  3.0 
28  0.7 2.0 2.6  1.4  1.0  1.0 
29  0.9 0.3 3.7  2.9  0.1  3.3 
30  2.2 0.1 2.1  1.5  1.8  0.5 
31  3.9 0.1 2.6  3.1  0.3  3.0 
32  0.8 0.8 1.47  2.8  0.5  3.4 
33  3.7 2.0 2.3  2.8  0.4  2.6 
34  2.2 0.3 2.4  3.4  1.02  3.9 
35  3.2 0.3 2.2  2.3  0.12  5.5 
36  3.42 3.0 4.3  4.4  1.0  0.5 
37  3.22 1.0 2.6  2.1  0.7  0.4 
38  1.2 1.5 3.0  2.7  2.8  5.0 
39  1.9 0.9 3.0  3.2  2.1  3.2 
40  1.2 2.21 2.4  1.9  2.7  2.6 
Mean  2.229  2.192  2.738  3.072*  2.548  3.147* 
SEM  0.212  0.208  0.086  0.136  0.220  0.198 
Pvalue  0.897  0.015  0.011 
No significant difference as compared with serum globulin levels after clarithromycin therapy,but  , significant difference as compared 
with serum globulin levels after roxithromycin & azithromycin  therapy at P<0.05 
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Fig. (13):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum globulin level, 
( M ±  SE , n =40). 
 
No significant difference as compared with serum globulin levels after clarithromycin 
therapy,but  , *significant difference as compared with serum globulin levels after 
roxithromycin & azithromycin  therapy at P<0.05 
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4.16 Effect of Clarithromycin on Serum Alkaline Phosphatase    
(ALP) Level 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days significantly increased on  serum alkaline phosphatase 
(ALP) level (239 ± 6.20 to 356.5 ± 17.95) U/L in the patients under digoxin 
therapy. The results presented in Table (10) and Figure (14). 
4.17 Effect of Roxithromycin on Alkaline Phosphatase (ALP) 
Level 
An oral administration of roxithromycin in a dose of 300 mg capsule once a 
day for 5 days no significant effect on serum alkaline phosphatase (ALP) 
level (341.7 ± 16.67 to 372.7 ± 14.32) U/L in the patients under digoxin 
therapy. The results presented in Table (10) and Figure (14). 
 
4.18 Effect of Azithromycin on Alkaline Phosphatase (ALP) 
Level 
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days significantly increased serum alkaline phosphatase (ALP) 
level (303.8 ± 13.85 to 355.7 ± 15.58) U/L in the patients under digoxin 
therapy. The results presented in Table (10) and Figure (14). 
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        Table (10): Serum ALP levels  before and after oral administration of clarithromycin  ,roxithromycin or azithromycin 
in the patients under digoxin therapy ,(M ± SE , n =40) 
Case No.  Serum ALP (U/L),after 
 Clarithromycin therapy. 
Serum ALP (U/L),after 
Roxithromycin therapy 
Serum ALP (U/L),after 
Azithromycin therapy 
Before  After  Before  After  Before  After 
1  202.0  480.0  190.0  212.0  477.0  430.0 
2  179.0  530.0  200.0  486.0  463.0  444.0 
3  301.0  239.0  381.0  420.0  481.0  247.0 
4  224.0  376.0  476.0  420.0  390.0  412.0 
5  230.0  461.0  264.0  445.0  302.0  227.0 
6  270.0  392.0  480.0  246.0  200.0  370.0 
7  261.0  252.0  305.0  413.0  194.0  384.0 
8  230.0  311.0  301.0  225.1  305.0  411.0 
9  351.0  520.0  202.0  372.8  471.0  431.0 
10  330.0  521.0  350.0  384.0  300.0  479.0 
11  230.0  284.0  306.0  412.0  468.0  429.0 
12  270.0  247.0  470.0  430.0  200.0  216.0 
13  261.0  221.0  410.0  480.0  300.0  371.0 
14  301.0  261.0  467.0  430.0  481.0  247.0 
15  220.0  301.0  200.0  215.0  304.0  412.0 
16  240.0  375.0  301.36  372.72  330.0  521.0 
17  259.0  400.0  471.0  431.0  230.0  284.0 
18  239.8  374.5  176.0  479.0  270.0  247.0 
19  231.0  255.0  468.0  429.0  261.0  221.0 
20  224.0  530.0  200.0  213.0  301.0  261.0 
21  230.0  239.0  383.0  485.0  220.0  301.0 
22  270.0  376.0  382.0  419.0  240.0  375.0 
23  261.0  461.0  477.0  430.0  259.0  400.0 
24  220.0  251.0  463.0  444.0  239.8  374.5 
25  240.0  311.0  481.0  247.0  231.0  255.0 
26  242.0  520.0  390.0  412.0  224.0  530.0 
27  260.0  521.0  302.0  227.0  230.0  239.0 
28  224.0  284.0  200.0  370.0  270.0  376.0 
29  179.0  247.0  194.0  384.0  261.0  461.0 
30  180.0  221.0  305.0  411.0  301.0  471.0 
31  220.0  252.0  471.0  431.0  284.0  300.0 
32  240.0  311.0  300.0  479.0  247.0  468.0 
33  259.0  520.0  468.0  429.0  221.0  200.0 
34  260.0  521.0  200.0  216.0  261.0  300.0 
35  224.0  284.0  300.0  371.0  301.0  481.0 
36  179.0  247.0  481.0  247.0  375.0  304.0 
37  180.0  221.0  304.0  412.0  400.0  330.0 
38  239.8  374.5  302.0  227.0  374.5  230.0 
39  223.0  529.0  300.0  370.0  255.0  270.0 
40  177.0  240.0  350.0  384.0  233.0  522.0 
Mean  239  356***  341  372  303  355* 
SEM  6.209  17.95  16.67  14.32  13.85  15.58 
P‐Value  0.000  0.114  0.013 
*significant difference as compared with serum ALP levels after  clarithromycin or azithromycin but , no significant difference 
as compare with serum ALP levels after  roxithromycin.therapy, at P<0.05. 
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Fig. (14):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum ALP level, 
(M ±  SE , n =40). 
 
*significant difference as compared with serum ALP levels after clarithromycin or 
azithromycin but , no significant difference as compared with serum ALP levels after 
roxithromycin.therapy, at P<0.05. 
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4.19 Effect of Clarithromycin on Serum Alanine Aminotransferase 
(SGPT) 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days produced no significant effect on serum alanine 
aminotransferase (SGPT) level ( 9.36 ± 0.522 to 9.058 ±0.559) U/L in the 
patients under digoxin therapy. The results presented in Table (11) and 
Figure (15). 
 4.20 Effect of roxithromycin on serum alanine aminotransferase 
(SGPT) 
An oral administration of roxithromycin in a dose of  300 mg tablet once a 
day for 5 days produced no significant effect on serum alanine 
aminotransferase (SGPT) level (12.25± 1.37  to 10.19±1.47 ) U/L  in the 
patients under digoxin therapy. The results presented in Table (11) and 
Figure (15). 
 4.21 Effect of azithromycin on serum alanine aminotransferase 
(SGPT) 
An oral administration of azithromycin in a dose of  500 mg capsule once a 
day for 3 days produced no significant effect on serum alanine amino 
transferase (SGPT) level (8.602± 0.58  to 8.813 ±  0.523)  U/L in the 
patients under digoxin therapy. The results presented in Table (11) and  
Figure (15). 
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                Table (11): Serum SGPTlevels  before and after oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy ,(M ± SE , n =40) 
Case 
No. 
Serum SGPT(U/L),  
after clarithromycin 
therapy. 
Serum SGPT (U/L),  
after roxithromycin 
therapy 
Serum SGPT (U/L),after  
Azithromycin therapy 
Before  after  Before  After  Before  After 
1  8.6  7.5 3.3 1.8 6.0 11.0 
2  16.0  12.0 4.1 8.4 8.8 10.1 
3  6.2  5.1 16.3 9.1 7.0 9.0 
4  7.2  12.5 3.5 4.3 9.0 14.0 
5  8.0  16.0 4.9 10.1 4.9 12.0 
6  5.7  7.1 11.0 4.9 4.2 9.3 
7  5.1  8.9 14.9 6.6 4.9 10.3 
8  6.1  12.1 10.7 8.1 13.0 14.0 
9  10.5  8.0 5.5 7.0 8.8 7.0 
10  18.0  14.0 15.0 9.2 10.0 8.9 
11  8.2  10.0 13.0 10.1 8.2 6.1 
12  11.0  14.4 4.1 4.6 8.8 12.0 
13  6.0  11.0 6.1 9.2 10.1 5.0 
14  8.8  10.1 14.0 9.1 13.0 17.0 
15  7.0  9.0 3.3 1.8 4.9 10.1 
16  9.0  14.0 9.24 6.95 11.0 4.9 
17  4.9  12.0 11.0 4.9 14.9 6.6 
18  4.2  9.3 14.9 6.6 10.7 8.1 
19  4.9  10.3 10.7 8.1 5.5 7.0 
20  8.8  14.0 7.0 12.0 15.0 9.2 
21  10.0  7.0 5.1 4.2 13.0 10.1 
22  8.2  8.9 8.6 6.0 4.1 4.6 
23  8.8  6.1 10.0 16.0 6.1 9.2 
24  10.1  12.0 4.0 3.5 14.0 9.1 
25  13.0  5.0 16.0 12.0 3.3 1.8 
26  9.0  17.0 5.7 12.9 9.24 6.95 
27  5.1  8.0 5.7 40.0 11.0 4.9 
28  10.0  6.9 34.0 21.0 14.9 6.6 
29  15.0  5.0 15.2 24.0 10.7 8.1 
30  11.0  4.9 14.2 14.0 7.0 12.0 
31  12.1  7.0 12.8 50.0 5.1 4.2 
32  10.8  4.9 23.0 8.5 8.6 6.0 
33  12.0  6.1 3.1 6.0 10.0 16.0 
34  10.2  6.9 42.0 3.6 4.0 3.5 
35  10.8  5.0 22.0 4.9 16.0 12.0 
36  5.1  4.9 13.0 6.1 1.8 8.8 
37  12.1  4.2 21.0 8.9 6.95 10.0 
38  15.0  4.9 31.0 6.1 4.9 8.2 
39  9.26  13.0 10.0 9.3 6.6 8.8 
40  8.8  11.2 11.2 8.0 8.1 10.1 
Mean  9.36  9.05  12.25  10.19  8.60  8.81 
SEM  0.52  0.559  1.37  1.47  0.58  0.523 
P.Value  0.66  0.300  0.758 
*No significant difference as compared with serum SGPT levels after new macrolides .therapy, at P<0.05. 
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Fig. (15):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum SGPT level, 
(M ±  SE , n =40). 
 
*No significant difference as compared with serum SGPT levels after new macrolides 
.therapy, at P<0.05. 
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4.22 Effect of clarithromycin on serum aspartate aminotransferase  
(AST) (SGOT) level :  An oral administration of clarithromycin in a dose  
of  500 mg tablet twice a day for 7 days produced no significant effect on 
serum aspartate aminotransferase (AST) (SGOT) level ( 20.78 ± 1.837 
to 20.69 ± 1.461 ) U/L in the patients under digoxin therapy. The results 
presented in Table (12) and Figure (16). 
4.23. Effect of roxithromycin on serum aspartate aminotransferase  
(AST) (SGOT) level: An oral administration roxithromycin in a dose of  
300 mg capsule once a day for 5 days produced no significant effect on 
serum aspartate aminotransferase (AST) (SGOT) level (21.82 ± 1.81 to 
20.17 ± 1.58) U/L in the patients under digoxin therapy. The results       
presented in Table (12) and Figure (16). 
4.24. Effect of azithromycin on serum aspartate aminotransferase  
(AST) (SGOT) level: An oral administration of azithromycin in a dose of  
500 mg capsule once a day for 3 days produced no significant effect on 
serum aspartate aminotransferase (AST) (SGOT) level (21.37 ± 1.42 to 
20.12  ± 1.36) U/L  in the patients under digoxin therapy. The  results 
presented  in Table (12) and Figure (16) 
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          Table (12): Serum SGOT levels  before and after oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy ,(M ± SE , n =40) 
Case 
No. 
Serum SGOT(U/L),  
after clarithromycin  
. 
Serum SGOT (U/L),  
after roxithromycin therapy 
Serum SGOT (U/L),after  
Azithromycin therapy 
Before  after  Before  After  Before  After 
1  12.2  40.0  20.0  19.2  21.0 17.5 
2  19.1  19.3  12.7  14.9  12.9 18.1 
3  29.0  13.1  21.0  16.0  13.2 13.1 
4  46.6  23.6  11.1  12.9  17.2 19.1 
5  28.0  20.0  13.1  18.7  20.8 20.1 
6  12.2  19.0  3.3  5.3  33.0 17.7 
7  30.0  19.1  27.6  21.8  21.9 18.7 
8  38.0  17.9  29.8  18.1  46.0 21.0 
9  15.2  47.0  19.0  14.9  23.0 18.0 
10  19.2  15.1  21.0  18.0  17.0 14.0 
11  12.8  17.5  38.0  22.1  13.1 45.0 
12  18.0  18.1  11.5  13.1  19.1 12.9 
13  21.0  13.1  12.9  15.0  20.1 13.2 
14  12.9  19.1  13.1  14.2  17.7 17.2 
15  13.2  20.1  22.0  30.0  20.8 18.7 
16  17.2  17.7  15.99  14.89  21.0 21.0 
17  20.8  18.7  45.0  37.0  35.0 16.0 
18  21.0  21.0  29.8  18.1  44.0 21.0 
19  21.9  18.0  19.0  14.9  15.0 18.8 
20  46.0  14.0  21.0  18.0  29.8 18.1 
21  23.0  19.0  28.0  48.0  19.0 14.9 
22  17.0  18.5  11.5  13.1  21.0 18.0 
23  35.0  16.0  12.9  15.0  28.0 48.0 
24  44.0  21.0  13.0  20.0  11.5 13.1 
25  15.0  18.8  12.7  14.9  16.0 15.0 
26  14.2  20.0  21.0  16.0  21.0 39.0 
27  12.8  20.0  12.0  12.9  25.0 21.0 
28  23.0  19.0  13.1  18.7  21.0 18.0 
29  4.9  34.0  20.0  15.3  12.0 12.9 
30  6.1  15.2  27.6  21.8  13.1 18.7 
31  8.9  14.2  28.0  22.1  20.0 17.0 
32  11.2  12.8  11.5  13.1  27.6 25.0 
33  6.1  23.0  5.0  12.9  28.0 27.0 
34  6.9  3.1  45.0  40.0  11.5 13.1 
35  5.0  12.9  25.0  21.0  10.0 12.9 
36  45.0  40.0  16.0  44.0  45.0 40.0 
37  25.0  21.0  36.0  14.0  14.9 11.1 
38  16.0  24.0  34.0  50.0  16.0 15.0 
39  24.0  14.0  50.0  16.0  12.9 18.0 
40  34.0  50.0  44.0  21.0  20.0 28.0 
Mean  20.78  20.69  21.82  20.17  21.37  20.12 
SEM  1.83  1.46  1.81  1.58  1.42  1.36 
PValue  0.968  0.342  0.438 
*No significant difference as compared with serum SGOT levels after  new macrolides therapy, at P<0.05. 
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Fig. (16):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum SGOT level,  
(M ±  SE , n =40). 
 
 
 
 
 
*No significant difference as compared with serum SGOT levels after  new 
macrolides therapy, at P<0.05. 
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5. Effects of Macrolides on  Electrolyte Levels  
  5.1 Effect of clarithromycin on serum sodium  level 
An oral administration of clarithromycin in a dose of 500 mg tablet  twice a 
day for 7 days significantly increased on serum sodium level  138.5 ± 0.933 
to 141.7 ± 0.849) mmol in the patients under digoxin therapy. The results 
presented in Table (13) and Figure (17). 
5.2 Effect of roxithromycin on serum sodium  level 
An oral administration of roxithromycin in a dose of  300 mg capsule once 
a day for 5 days significantly increased on serum sodium level ( 138 ± 
0.893 to 141.9 ± 0.926 ) mmol in the patients under digoxin therapy. The 
results presented in Table (13) and Figure (17). 
5.3 Effect of azithromycin on serum sodium  level 
An oral administration of azithromycin in a dose of  500 mg capsule once a 
day for 3 days significantly increased on serum sodium level (138.5 ± 
0.821 to 141.5 ± 0.832 ) mmol in the patients under digoxin therapy. The 
results presented in Table (13) and Figure (17). 
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Table (13): Serum Sodium levels  before and after oral administration of clarithromycin  ,roxithromycin or in the patients under 
digoxin therapy ,(M ± SE , n =40) 
Case No.  Serum sodium (mmol) , after 
clarithromycin therapy. 
Serum sodium (mmol) , after 
roxithromycin therapy. 
Serum sodium (mmol) , after azithromycin therapy. 
before  after  Before  after  before  after 
1  139.0  141.0  150.0  153.0  139.0  141.0 
2  137.0  134.0  136.0  138.0  137.0  134.0 
3  141.0  144.0  133.0  138.0  141.0  144.0 
4  136.0  142.0  136.0  145.0  136.0  142.0 
5  144.0  135.0  139.0  150.0  144.0  135.0 
6  150.0  153.0  135.0  144.0  150.0  153.0 
7  136.0  138.0  136.0  138.0  136.0  138.0 
8  133.0  138.0  155.0  141.0  133.0  138.0 
9  136.0  145.0  152.0  155.0  136.0  145.0 
10  139.0  150.0  131.0  137.0  139.0  150.0 
11  135.0  144.0  139.0  145.0  135.0  144.0 
12  136.0  138.0  135.0  144.0  136.0  138.0 
13  155.0  141.0  132.0  138.0  155.0  141.0 
14  152.0  155.0  136.0  138.0  152.0  155.0 
15  131.0  137.0  138.0  144.0  131.0  137.0 
16  139.0  145.0  138.0  143.0  139.0  145.0 
17  135.0  144.0  138.0  137.0  135.0  144.0 
18  132.0  138.0  145.0  140.0  132.0  138.0 
19  136.0  138.0  138.0  146.0  136.0  138.0 
20  137.0  145.0  138.0  147.0  138.0  144.0 
21  141.0  140.0  134.0  140.0  136.0  138.0 
22  130.0  136.0  138.0  146.0  134.0  134.0 
23  134.0  132.0  141.0  137.0  135.0  135.0 
24  136.0  142.0  138.0  146.0  142.0  142.0 
25  140.0  144.0  138.0  138.0  144.0  144.0 
26  140.0  142.0  148.0  145.0  140.0  139.0 
27  138.0  140.0  132.0  132.0  137.0  140.0 
28  150.0  136.0  135.0  136.0  136.0  138.0 
29  151.0  154.0  134.0  135.0  134.0  134.0 
30  132.0  138.0  135.0  145.0  137.0  134.0 
31  136.0  143.0  144.0  145.0  138.0  141.0 
32  140.0  149.0  135.0  130.0  139.0  143.0 
33  134.0  140.0  137.0  141.0  136.0  137.0 
34  135.0  139.0  138.0  141.0  146.0  140.0 
35  136.0  146.0  135.0  137.0  136.0  146.0 
36  142.0  141.0  145.0  130.0  139.0  147.0 
37  133.0  139.0  135.0  149.0  132.0  145.0 
38  136.0  134.0  138.0  148.0  139.0  143.0 
39  141.0  145.0  130.0  151.0  142.0  152.0 
40  137.0  145.0  131.0  145.0  140.0  145.0 
Mean  138.5  141.7**  138  141.9**  138  141.5** 
SEM  0.933  0.849  0.893  0.926  0.821  0.832 
P.Value  0.001  0.001  0.001   
* significant difference as compared with serum sodium levels after  new macrolides .therapy, at P<0.01. 
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Fig. (17):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or in the 
patients under digoxin therapy , on serum sodium level,( M ±  SE , n =40). 
 
 
* significant difference as compared with serum sodium levels after  new macrolides 
.therapy, at P<0.01. 
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5.4. Effect of clarithromycin on serum  potassium level 
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days   significantly decreased serum potassium level (4.877± 
0.156 to 4.01 ± 0.105 ) mmol in the patients under digoxin therapy. The 
results presented in Table (14 ) and Figure (18 ). 
5.5  Effect of roxithromycin on serum potassium  level  
An oral administration of roxithromycin in adose of 300 mg capsule once a 
day for 5 days (5.0 9 ± 0. 135 to 4.23  ± 0.112 )significantly decreased 
serum potassium level  mmol in the patients under digoxin therapy.The 
results presented in Table (14) and Figure (18) 
5.6 Effect of azithromycin on serum potassium  level  
An oral administration of azithromycin in a dose of 500 mg capsule once a 
day for 3 days significantly decreased serum potassium level(4.765± 0.105 
to 4.13  ± 0.104 ) mmol in the patients under digoxin therapy. The results 
presented in Table (14) and Figure (18). 
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                                        Table (14): Serum potassium levels  before and after oral administration of clarithromycin  ,roxithromycin 
or azithromycin in the patients under digoxin therapy ,(M ± SE , n =40) 
Case 
No. 
 Serum potassium(mmol) , after 
clarithromycin therapy. 
Serum potassium(mmol) , after 
roxithromycin therapy. 
Serum potassium(mmol) , after 
azithromycin therapy. 
Before  After   Before   After  before  After  
1  3.7  3.7  6.0  5.1  3.8  3.7 
2  4.6  4.3  5.3  4.7  4.4  4.3 
3  5.5  5.0  5.8  4.1  4.5  5.0 
4  3.9  3.0  7.4  5.3  3.6  3.0 
5  3.1  3.5  5.9  4.6  3.5  3.5 
6  3.6  3.5  5.6  5.4  4.6  3.5 
7  4.3  3.9  4.7  4.5  5.3  3.9 
8  4.5  3.6  5.2  3.6  5.5  3.6 
9  6.0  4.6  4.8  5.5  5.0  4.6 
10  3.9  3.5  5.1  4.8  4.9  3.5 
11  4.3  4.0  4.3  3.7  3.3  4.0 
12  5.5  3.3  4.9  4.3  4.5  3.3 
13  5.2  4.6  5.6  4.2  4.2  4.6 
14  4.6  3.0  4.7  5.1  5.6  3.0 
15  3.7  3.7  5.9  4.3  4.7  3.7 
16  5.7  3.8  5.5  4.0  4.7  3.8 
17  4.7  4.8  5.1  3.9  5.7  4.8 
18  4.7  4.0  7.0  5.5  3.7  4.0 
19  5.5  4.9  4.9  3.7  4.5  4.9 
20  3.1  3.0  5.9  4.9  4.1  3.0 
21  6.1  3.5  5.2  3.7  5.0  3.5 
22  7.2  4.1  4.3  3.6  4.3  4.1 
23  6.1  4.2  6.1  5.6  4.8  4.2 
24  4.9  4.1  5.6  4.1  6.4  4.1 
25  4.5  4.3  5.4  4.1  5.2  4.3 
26  5.5  4.0  3.8  3.7  4.6  4.0 
27  5.0  4.4  4.4  4.3  4.7  4.4 
28  4.9  4.2  4.5  5.0  5.2  4.2 
29  4.2  4.6  3.6  3.0  4.8  4.6 
30  4.9  4.4  3.5  3.5  5.1  4.4 
31  4.0  4.1  4.6  3.5  4.3  4.1 
32  3.4  3.0  5.3  3.9  4.9  3.0 
33  6.1  4.3  5.5  3.6  5.6  4.3 
34  7.2  5.3  5.0  4.6  4.7  5.3 
35  6.1  6.0  4.9  3.5  5.8  6.0 
36  5.1  4.6  3.3  4.0  4.9  4.6 
37  4.5  3.3  4.5  3.3  5.7  3.3 
38  5.4  3.6  4.2  4.6  4.6  3.6 
39  5.0  3.6  5.6  3.0  4.9  3.6 
40  4.9  3.3  4.7  3.7  5.0  3.3 
Mean  4.877  4.015***  5.09  4.23***  4.76  4.13*** 
SEM  0.156  0.105  0.135  0.112  0.105  0.104 
P‐
Value 
0.000  0.000  0.000 
* significant difference as compared with serum potassium levels after new macrolides .therapy, at P<0.001. 
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Fig. (18):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or in the 
patients under digoxin therapy , on serum potassium level,( (M ±  SE , n =40). 
 
 
* significant difference as compared with serum potassium levels after new macrolides 
.therapy, at P<0.001. 
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5.7  Effect of clarithromycin on serum  calcium level  
An oral administration of clarithromycin in a dose of 500 mg tablet twice a 
day for 7 days   significantly increased on serum calcium level (8.19± 0.09 
to 8.79 ± 0.113) mg/dl in the patients under digoxin therapy. The results  
present in Table (15) and Figure (19) 
5.7. Effect of roxithromycin on serum calcium  level  
An oral administration of roxithromycin in a dose of  500 mg capsule once 
a day for 3 days significantly increased on serum calcium level (8.3 ± 0.108 
to 8.5 ± 0.086) mg/dl in the patients under digoxin therapy. The results 
present in Table (15) and Figure (19).  
5.8. Effect of azithromycin on serum calcium  level  
An oral administration of azithromycin in a dose of  500 mg capsule once a 
day for 3 days significantly increased on serum calcium level (8.38 ± 
0.106to 8.65 ± 0.113) mg/dl in the patients under digoxin therapy. The 
results present in Table (15) and Figure (19). 
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                                           Table (15): Serum calcium levels before &after oral adminisration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy ,(M ± SE , n =40) 
 
*significant difference as compared with serum calcium levels after  new macrolides.therapy, at P<0.05 
 
Case No.  Serum calcium (mg/dl), after 
clarithromycin therapy 
Serum calcium (mg/dl), after 
roxithromycin therapy 
Serum calcium (mg/dl), after 
azithromycin therapy 
Before  After  Before  After  Before  After 
1  8.3  9.2  8.2 8.2 8.0 8.1 
2  8.9  10.0  8.5 7.6 8.3 9.1 
3  7.9  8.0  8.2 8.6 7.8 8.2 
4  7.9  8.6  7.5 7.7 8.8 9.1 
5  8.1  9.3  8.0 8.6 7.7 8.2 
6  7.9  8.5  8.1 9.1 9.0 9.1 
7  7.9  8.4  8.0 7.9 8.3 8.3 
8  7.6  8.1  9.0 9.1 9.0 7.9 
9  8.4  9.1  7.6 8.7 7.3 7.8 
10  7.6  8.1  8.1 8.0 8.8 8.1 
11  8.4  8.9  8.6 8.1 7.8 9.5 
12  7.9  8.2  9.9 9.5 8.7 8.4 
13  8.1  9.0  8.0 7.7 7.9 9.1 
14  8.7  9.1  8.7 8.5 8.3 8.5 
15  8.4  9.5  8.6 8.6 7.8 8.8 
16  9.0  9.4  8.7 8.6 9.1 8.1 
17  7.3  8.0  8.0 8.7 7.9 8.0 
18  8.5  8.0  7.7 8.1 9.1 9.0 
19  8.3  9.0  8.0 9.1 8.7 7.6 
20  7.8  8.6  7.5 8.2 8.0 8.1 
21  9.2  9.9  8.5 9.1 8.1 8.6 
22  7.4  8.0  7.4 8.2 9.5 9.9 
23  8.2  8.7  8.7 9.1 7.7 8.0 
24  8.3  8.6  8.0 8.3 8.5 8.7 
25  7.3  7.9  8.7 7.9 8.6 8.6 
26  8.2  9.1  7.0 7.8 7.3 7.9 
27  7.7  8.7  8.5 8.1 8.5 9.1 
28  8.5  9.9  7.5 9.5 8.0 8.7 
29  8.3  9.5  8.4 8.4 8.8 9.9 
30  7.9  8.2  7.6 9.1 8.6 9.5 
31  7.5  8.1  8.0 8.5 8.1 8.2 
32  8.6  8.9  8.8 9.0 7.8 8.1 
33  8.9  8.9  9.2 7.9 8.9 8.9 
34  7.6  7.5  7.5 8.0 9.1 8.9 
35  8.8  9.6  8.5 9.0 7.9 7.5 
36  9.0  10.1  8.9 8.9 9.1 9.6 
37  10.0  10.4  8.9 9.1 9.3 10.1 
38  7.6  8.8  7.5 7.9 10.3 10.4 
39  7.0  7.9  9.6 9.1 7.9 8.8 
40  8.8  8.0  10.1 9.3 7.0 7.9 
Mean  8.19  8.79***  8.3  8.5*  8.38  8.65** 
SEM  0.096  0.113  0.108  0.086  0.106  0.113 
P‐value  .000  0.047  0.007 
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Fig. (19):  Effect of  an  oral administration of clarithromycin  ,roxithromycin or 
azithromycin in the patients under digoxin therapy , on serum calcium level, 
 (M ±  SE , n =40). 
 
 
 
*significant difference as compared with serum calcium levels after new macrolides 
therapy, at P<0.05. 
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6. Case Report 
A 46 year-old woman with history of  heart failure , was being treated with 
digoxin 0.25mg once a day and  spironolactone 25mg three times daily for 
the past ten years. She presented to Ibn –sina hospital with fever and cough 
for 5 days. Clarithromycin 500 mg tablet  twice a day  was prescribed by 
the physician for presumed community acquired pneumonia.  
Two days after clarithromycin  therapy , the patient developed profound 
weakness associated with nausea, vomiting, and dizziness. On examination 
pulse rate was 122 /minute and blood pressure was 60/40 (mm Hg). ECG 
showed tachycardia, and hypotension . Figure (20).  
 Laboratory results revealed digoxin level of 3.99 ng/ml (therapeutic range 
= 0.8-2 ng/ml). 
The patient was shifted to ICU and all medications were discontinued  and 
continued only on frosemide 20 mg  injection. Lidocaine in dextrose drip 
then dopamine 200 mg was  add to infusion to raise the blood pressure.  
Her condition deteriorated at night and  adrenaline and atropine iv. were 
added  to save her life, and after continued care, they saved her life. 
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Fig. (20): ECG of case report 
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7. Case Report 
A  60 year-old man with history of diabetesmellitus type one, and  
congestive  heart failure , was being treated with digoxin 0.25mg once a 
day and  aldactone (spironolactone) 50mg once  daily for the past  20 years. 
Three days previously, he had been admitted to clinic for treatment of a 
urinary tract infection. Roxithromycin 300 mg tablet once a day was 
prescribed by the physician .He presented to Emergency Unit of Ibn –sina 
hospital. After three days ]of administration of  roxithromycin therapy, 
weakness associated with nausea, vomiting, and diarrhea ,profound in the 
patient . On examination ,pulse rate was 60 bpm and blood pressure was 
130/80 (mm Hg). ECG showed digoxin toxicity firstly and H block finally 
in ICU. Figure (21).  
 Laboratory results revealed digoxin level of 4.3 ng/ml (therapeutic range = 
0.8-2 ng/ml). 
The patient was shifted to ICU and all medications were discontinued and 
continued only on sol. insulin. Injection glucose 40%  in dextrose 5% drip 
then his condition worsened at night. Dopamine 200 mg was added in the 
infusion to raise the blood pressure .Also NaHCO3, omeprazol, frusemide 
20 mg  ,atropine, aminophyllin and cal. gluconate iv. were added  to save 
his life, after continuds care  until died from heart block  . 
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Fig. (21): ECG of case report 
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Discussion 
Digoxin is a useful adjunctive medication in the treatment of congestive heart failure 
and atrial fibrillation .However, it has a narrow therapeutic index and multiple, well-
known drug interactions (76).  
Erythromycin-digoxin interaction has been reported in many case reports, (6, 153) 
however ,new macrolides induced digoxin toxicity is less well recognized. Several 
studies are available that provide insights into this point. A retrospective Canadian 
review of more than 1000 patients with digoxin toxicity revealed that patients who had 
taken clarithromycin during the previous week were 12times more likely to develop 
toxicity than those patients who did not take clarithromycin (94) 
 A Japanese study of 8 hospitalized patients showed that digoxin concentrations were 
on average 70% higher in patients treated with clarithromycin when given their usual 
digoxin dose (54). 
A prospective observational Spanish study showed digoxin levels were higher in all 7 
patients who were prescribed a 5- to 7-day regimen of oral clarithromycin concurrent 
with digoxin therapy. (154) Elevated digoxin levels, lower clearance rates, and increased 
digoxin half-life occurred in all patients (154). However, only 1 patient who had reduced 
renal function developed signs of digoxin toxicity. (155) . These studies suggest that 
concurrent use of digoxin and clarithromycin elevates digoxin levels. 
Introduction of newer macrolides with structural modifications resulted in compounds 
with not only varying antibacterial activity but also variability in their potential for 
interactions with other drugs (9).  
This study  gives us a strong  agreement with previous studies of  there were a relation  
between digoxin concentration and administration of new macrolides it shows that 
clarithromycin in a dose 500 mg tablet twice a day for 7 days, roxithromycin  in a dose 
of 300 mg tablet once a day for 5days,  and azithromycin in a dose 500 mg capsule once 
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a day for 3 days, caused significant increase  serum digoxin and creatinine levels in the 
patients under digoxin treatment .this  could be explained at least in part , due to  
decreased renal digoxin clearance as reflected by significantly rised serum creatinine 
level within normal range of renal function .  
Lindenbeum reported that 10% of the population converts 40% of an oral digoxin in a 
dose to dihydro (reduced)  metabolites (DRM), which are much less cardio active than 
digoxin (109).These individuals require increased digoxin doses to achieve therapeutic 
concentrations It was then shown that E. lentum was the microorganism (anaerobic 
bacillus)  responsible for this conversion (112). E. lentum is a normal component of the 
gut flora , It is unknown why only a certain percentage of people produce DRMS ,but it 
has been postulated that it may be due to genetic makeup and the natural environment 
during early development (108). 
Administration of new macrolides reduces the population of E. lentum, which decreases 
the conversion of digoxin to DRM, thus increasing the bioavailability of digoxin. (128) 
While two thirds of the population excretes less than 5% of a digoxin dose as DRM , 
10% of the population converts up to 40% of a digoxin dose to DRM. This population 
is at an increased risk for developing toxic digoxin levels when gastrointestinal flora is 
altered by antibiotic use (129). 
Several case reports describe patients with previous stable digoxin levels who 
developed digoxin toxicity induced by the administration of clarithromycin, 
roxithromycin, and azithromycin (103,109).  
Pai, Gracie, & Amsden reported that "several mechanisms exist by which the 
macrolides interact with other drugs" (131).The inhibition of the cytochrome P450 
enzyme system is the most common mechanism, particularly CYP3A4 and  CYP1A2 
(82,152). 
According to Edmunds and Mayhew, clarithromycin inhibits their metabolism. Toxicity 
occurs because of the enzyme inhibition (187). 
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Clarithromycin's active metabolite is 14-OH-clarithromycin (14OHC) which is 
metabolized by CYP3A4 to metabolites which form complexes with heme (iron) 
molecules of cytochrome , causing CYP3A4 to lose catalytic ability resulting in 
elevated serum levels of drugs cleared by the hepatic CYP450 oxidizing system (3,162). 
However, Yamazaki and Shimada reported that roxithromycin itself is not as potent an 
inhibitor of CYP3A4 activities as are troleandomycin and erythromycin, probably 
because of the slower metabolism of this compound to metabolites ,but, they found that 
N-monodemethyl derivative (M3), in rats, dogs, and humans have been shown to inhibit 
CYP3A catalytic activities by forming inactive P450zFe21-metabolite complexes after 
metabolic activation; these events have been implicated as being one of the mechanisms 
causing drug-drug interactions when macrolide antibiotics are administered 
simultaneously with other drugs to human patients (127 ). 
Also Yamazaki and Shimada et al showed that the N-demethylamine derivative (M3) of 
roxithromycin is a more potent inhibitor of CYP3A4, after activation by CYP3A4 itself, 
than is the parent drug roxithromycin. Formation of inhibitory P450zFe21-metabolite 
complexes is shown to be required for the inhibitory action (127). 
The previous hypothesis , from rat studies, that formation of a nitrosoalkane derivative 
that attacks the P450 enzyme is critical for potent inhibition is consistent with the 
results of this study using human enzyme preparations. The weak abilities of 
roxithromycin to inhibit CYP3A4 may be the result of the slower metabolism of this 
compound to M3 and other metabolites in humans (127) . 
On the other hand, azithromycin is believed to be metabolized to an inactive metabolite 
via N-demethylation through other routes independent of the CYP system 
(156,157,158,159,176).This phenomenon may be directly related to azithromycin's structure. 
This illustrates the metabolism of macrolide antibiotics (176). 
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In vitro and in vivo studies in rats and humans have shown that azalides do not 
significantly inhibit hepatic microsomal enzymes or produce enzyme-metabolite 
complexes (126,158). 
Gillum reported that azithromycin is free of the CYP3A4 effects and is considered safe 
for use with another CYP3A4-metabolized drug. Azithromycin is safer than 
clarithromycin (82).  
There are other theories as to why macrolides increase serum digoxin concentrations.  
One theory suggests that macrolides may affect gut motility and thereby increase the 
bioavailability of digoxin; however this is less likely as other prokinetic agents have 
been shown to decease the bioavailability of digoxin (110).It is also possible that a 
disease state such as acute infection will have an effect on the CYP450 enzyme system. 
Drug metabolism can be slowed by interferon-related suppression of CYP450 activity 
(82).Others propose a different mechanism of interaction, which involves macrolide 
inhibiting P-glycoprotein-mediated tubular secretion of digoxin (111). Also the patients 
with hypoalbuminemia will have free digoxin or active drug available so leading to 
digoxin toxicity (114). 
All of these theories mentioned above may explain the increase of serum digoxin level 
that leads to digoxin toxicity .Moreover ,toxicity signs appeared clearly in our study 
after clarithromycin, roxithromycin  and azithromycin therapy 
Digoxin is primaring eliminated by the kidney, and the mechanism of renal clearance 
involves glomerular filtration tubular secretion,and reabsorption (164). 
Digoxin is transported by P-glycoprtein, a member of the adenosine triphosphate-
binding casstte family of tubular secretion of digoxin .This is decreased by new 
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macrolides and that might contribute to the mechanism of digoxin –macrolides 
interaction (162,163). 
14-OH-clarithromycin undergoes significant renal elimination about 46%-54% (47, 49).So 
the concentration of it in the kidney is more than roxithromycin and azithromycin which 
mainly biliray eliminated (111,188).  
The effect of clarithromycin on P-glycoprotein –mediated transport of digoxin was 
investigated with use of the cell monolayers, which can characterize drug interactions 
with digoxin (184). 
Roxithromycin and azithromycin may increase digoxin level by inhibiting the P-
glycoprotein efflux pump of the bile canalicular membranes of hepatocytes  .  
Schinkel reported that mdr l knockout mice , which lack the mouse mdr l a P-
glycoprotein ,showed markedly higher plasma concentrations of digoxin with slower 
elimination from the body compared with wild type animals (163,167,168). 
 P-glycoprotein may therefore be a pharmacokinetic and pharmacologic determinant of 
digoxin and could contribute to the interactions observed between digoxin and other 
drugs in patients (189). 
Based on animal model studies, investigators have postulated that typical substrates for 
P-glycoprotein are hydrophobic, neutral and/or cationic (165,166) .Both erythromycin and 
clarithromycin inhibit P-glycoprotein in various tissues, thereby increasing serum 
concentrations of drugs eliminated through this efflux pump (64,111). 
No data exists regarding the affinity of roxithromycin and azithromycin for P-
glycoprotein, roxithromycin and  azithromycin have the characteristics of a potential 
substrate: biliary elimination, & lipophilicity. If the P-glycoprotein efflux pump affects 
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azithromycin and roxithromycin, could be  interfere with digoxin clearance, thereby 
increasing digoxin concentrations in the blood. 
Classic digoxin toxicity symptoms as  nausea and vomiting were observed after  
clarithromycin,roxithromycin  and azithromycin in the patients under digoxin treatment. 
Hurwitz found that nausea or vomiting are common symptoms and can occur early in 
the course of digitalis intoxication and  were the most common but diarrhea and even 
abdominal pain may be a part of the syndrome  degree according to each drug  activity 
(175) . 
Also  the results in this study were in agreement with those reported by Mahdyoon et al 
(190) showing that nausea and vomiting are primarily due to a direct action of digitalis to 
excite the chemoreceptor trigger zone (CTZ) in the area postrema of the medulla rather 
than to a direct irritant action on the gastrointestinal tract (107).        
In elderly patients in whom there is a high prevalence of gastrointestinal tract 
complaints, it is often difficult to identify gastrointestinal tract symptoms of toxicity. It 
has been suggested that the elderly more often have anorexia rather than nausea and 
vomiting as toxic symptoms and approximately 45% of patients with life threatening 
toxicity present with nausea or vomiting (175). 
In our study we found that clarithromycin in the patients under digoxin therapy, 
produced non significant effect on the liver function enzymes (serum alanine 
aminotransferase (ALT) (SGPT), aspartate aminotransferase  (AST) (SGOT), direct 
bilirubin, albumin ,globulin,  and total protein levels), except serum alkaline phosphtase 
and serum total bilirubin which were significantly increased  . 
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On the other hand ,roxithromycin, and azithromycin in the patients under digoxin 
therapy, induced  a significant  increase in serum globulin, but , in serum albumin level 
they produced a significant decrease, Non significant effect on the liver function 
enzymes (serum alanine aminotransferase (ALT) (SGPT), aspartate aminotransferase  
(AST) (SGOT), and total protein.  
Azithromycin, induced a significant increase in serum alkaline phosphtase and serum 
total bilirubin levels.  But , roxithromycin, induced a significant  increase on serum 
direct bilirubin. 
Elevated of alkaline phosphatase (ALP) was not due to direct effect of clarithromycin 
and azithromycin therapy in the patients under digoxin treatment, but may be due to 
primary biliary cirrhosis, alcoholic hepatitis, gallstones in choledocholithiasis and bone 
problems in the elderly patients (169). 
Such elevation may be due to inadequate improvement of state of congestive heart 
failure. Dunn observed that the improvement in the congestive heart failure returns the 
elevated levels of alkaline phosphatase to normal (169).  
Both clarithromycin and azithromycin caused increase serum total bilirubin ,but 
roxithromycin only caused increase serum direct bilirubin level and the total bilirubin, 
has undergone conjugation (that is hepatic cell metabolism), and at portion of bilirubin 
which has not been metabolized.  
The exact pathogensis of hyperbilirubinemia was a matter of debate among workers. 
Eppinger , related the elevation of the serum bilirubin in patients with congestive heart 
failure to cholestasis produced by compression of the bile canaliculi by dilated vein 
.This finding is in agreement with our results(112)  
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On the other hand   ,Losowsky ,stated that does not seem to play a significant role in the 
elevation of serum bilirubin levels in patients with congestive heart failure, a hemolytic 
factor might be implicated (112,169). Obstruction of the bile ducts anther caused to 
increase t. bilirubin levels, reflected as deficiencies in bilirubin excretion (169) 
 If total bilirubin is normal as we found in our results after roxithromycin therapy which 
increased significantly d.bilirubin   , this problem may be due to   an excess of 
unconjugated bilirubin, and the location of the problem is upstream of bilirubin 
excretion. Hemolysis, viral hepatitis, or cirrhosis can be suspected (136) 
The decrease in the albumin level after roxithromycin and azithromycin therapy in the 
patients under digoxin treatment, may be  due to the liver being chronically  damaged. 
This would indicate that the synthetic function of the liver has been markedly 
diminished. Such findings suggest a diagnosis of cirrhosis. Other reason to decrease in 
albumin level is a combination of severe illness with prolonged protein deprivation 
eventually reflected in a reduced serum albumin level. Malnutrition which cause 
hypoalbuminemia with no associated liver disease ,or dehydration (180,181,182). 
In the liver functional disease there is a hypoalbuminaemia. At the same time globulin 
rise, this finding is in agreement with our results after roxithromycin and azithromycin 
therapy.  (177). 
Patients with hypoalbuminemia will have freer digoxin or active drug available that 
lead to digoxin toxicity (114). 
On the other studies recorded   that roxithromycin and azithromycin has a signinficant 
effect on the liver cells  (may be liver damage) its hepatotoxicity  (side effect ) (193), but 
, new macrolides in our studies produced non significant effect on liver enzymes  SGOT 
& SGPT  
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A variety of electrolyte abnormalities may occur in digioxin poisoning. Hypokalemia 
enhances myocardial automaticity and is potentially arrhythmogenic. The net effect of 
hypokalemia is intensification of digitalis-related tachydysrhythmias (170,171). 
This study shows that clarithromycin ,roxithromycin, and azithromycin induced 
significantl increase in  serum sodium and calcium level ,on other wise  produced a 
significant decreased in serum potassium   level . 
Researchers have only recently elucidated the complex electrophysiology of digitalis 
cardiotoxicity (177,179). Essentially, high levels of digitalis poison the myocardial Na-K-
ATPase pump and cause abnormally enhanced intracellular entry of sodium and 
calcium, along with egress of potassium. The excessive entry of intracellular potassium 
increases myocardial automaticity, enhances excitability, and may lead to the formation 
of delayed after depolarizations in transmembrane potentials following full 
repolarization. Digitalis-induced enhanced automaticity, excitability, and delayed after 
depolarizations contribute to the development of ectopy and tachydysrhythmias. On the 
other hand, the vagal effect and AV node depression produced by the glycosides result 
in bradydysrhythmias and AV blocks(177,179). 
Diarrhea , vomiting combined with a poor diet , all of these lead to abnormalities of 
potassium and sodium levels .On the other hand ,hypovolemia  related to inadequate 
intake of water, typically occur in elderly or otherwise disabled patients who are unable 
to take in water as their thirst dictates. This is the most common cause of  
hypernatremia, and excessive losses of water from the urinary tract, which may be 
caused by glycosuria, or other osmotic diuretics. . May be water losses associated with 
extreme sweating. or severe watery diarrhea can be cause hypernatremia (192 ). 
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Conversely, in chronic digoxin poisoning, hypokalaemia is more common, for two main 
reasons. Firstly, the blockade of sodium potassium pumps occurs gradually over a 
period of time, allowing the excess extracellular potassium to be excreted in the urine. 
Secondly, many patients chronically receiving digoxin are on potassium wasting 
diuretics.(152 ) 
The present study suggests that digoxin toxicity and electrolyte abnormality were the 
main reasons of the arrhythmiases that occured in the two cases compared before and 
after new macrolides administration. 
1. Case Report  
The patient described in our report presented to ICU after experiencing classic 
symptoms of digoxin toxicity including gastrointestinal effects ,and her  serum digoxin 
concentration was elevated two days after clarithromycin therapy .This put her at risk 
for cardiac arrhythmias due to digoxin toxicity. 
Interaction between macrolide antibiotics and other commonly used medications is now 
a frequent occurrence. One of the most likely explanations is the property of macrolide 
antibiotics, especially newer macrolides with structural modifications resulted in 
compounds with not only varying antibacterial activity but also variability in their 
potential for interactions with other drugs (172). 
In this case we have described potential drug interaction between clarithromycin  and  
digoxin. Patient presented had been compliant with the prescribed doses of digoxin for 
years without any problems. Introduction of clarithromycin to her regimen exposed her 
to hypokalemia which enhances myocardial automaticity and is potentially 
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arrhythmogenic. The net effect of hypokalemia is intensification of digitalis-related 
tachydysrhythmias. The serious adverse drug interactions between these drugs with the 
development of life threatening arrhythmias Therefore we highlight serious drug 
interactions of commonly prescribed antibiotics in patients on long term digoxin 
therapy (166,173.174). 
2. Case Report  
The patient described in our report presented to ICU after experiencing classic 
symptoms of digoxin toxicity including weakness associated with nausea, vomiting, and 
diarrhea.The digoxin level was markedly elevated at 4.3 ng/mL  (normal range, 0.8–2.0 
ng/mL). 
This case represents a probable interaction between digoxin and roxithromycin. Other 
significant contributing factors to the patient’s condition include renal dysfunction, 
possibly related to dehydration, which may have lead to digoxin accumulation. His age 
and preexisting diabetes mellitus may have also placed him at an increased risk for 
renal failure. Renal excretion of digoxin occurs in an exponential fashion and is 
proportional to the glomerular filtration rate. (189) 
 
In the patient with abnormal renal function, digoxin’s typical half-life of 36 to 48 hours 
may be prolonged.  Renal clearance of digoxin accounts for approximately 80% of total 
digoxin clearance. 
 
Electrolyte abnormalities may predispose to digoxin toxicity.14 electrolyte 
abnormalities, such as hypokalemia, hypomagnesemia, and hypercalcemia Various 
drugs also play a role in digoxin toxicity.(186) 
 
123 
 
Finally,   Other medication interactions must also be considered certain drugs  which 
increase both oral availability and intestinal absorption of digoxin,namely 
roxithromycin, quinidine, amiodarone, itraconazole,verapamil, cyclosporine, 
propafenone, and spironolactone. 
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Conclusion 
1. New macrolides (Clarithromycin , roxithromycin ,and azithromycin ) significantly       
increased serum digoxin level in  patients under digoxin treatment .  
2. New macrolides significantly increased serum creatinine level in the patients under 
digoxin treatment. 
3. New macrolides caused digoxin toxicity with classic symptoms (nausea or vomiting) 
in the patients under digoxin treatment. 
4. Clarithromycin and azithromycin increased significantly serum alkaline phosphatase 
(ALP), total bilirubin levels, but roxithromycin, and azithromycin significantly 
decreased serum albumin level in the patients under digoxin treatment. 
5. Roxithromycin and azithromycin macrolides increased significantly  serum globulin 
level.   
6. New macrolides had no significant effect on serum alanine aminotransferase (SGPT), 
aspartate aminotransferas (SGOT) level in the patients under digoxin treatment 
7. Roxithromycin produced significant increase in serum d.bilirubin, levels in the 
patients under digoxin therapy. 
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8. New macrolides   produced no significant effect on serum total protein level in the 
patients under digoxin treatment. 
9. New macrolide increased significantly serum calcium level and serum sodium level, 
but significantly decreased serum potassium level in the patients under digoxin 
treatment. 
10- Two patient intered to ICU due to uncontrolled of arrhythmia of clarithromycin and 
roxithromycin with digoxin interaction. 
 
Recommendations 
1- To increase the number of trials and studies of new generation of macrolides on 
digoxin patients. 
2- Recommended the erection of a National Toxicity Center to facilitate such research.  
3- Need to avail monitoring digoxin levels & rendering available anti dote therapy 
whenever digoxin toxicity arises. 
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Sheet (1) 
Serial No: 
Name:                                  Age:               sex: 
Occupation:                           Residence:                                 phone: 
Marital status:                       
 Education:          illiterate□   partially educated□    highly educated□  
  
 
Chief complaint: 
 
History of present illness: 
 
Accompanying symptoms: 
Fatigue , shortness of breath, exertional palpitations, palpitations at rest  
Dizziness , faintness, chest pain ,calf pain  
 
Digitalis toxicity symptoms: 
 
 
Drug history: 
Pre-admission drugs------------------------------------------------- 
The currently used drugs ………………………….. 
Doses……………… 
Interactions……………………… 
 
physical signs: 
vital signs: 
pulse rate :………………,respiratory rate :……………..,BP:……….. 
Temperature:…………….. 
Body weight……………..        
Pallor-----------, Jaundice--------------, dyspnoea------------- Heart murmurs: ---------------------------------
---------- 
Abdomen: hepatomegaly----------------, Splenomegaly--------------others----------     
--, limbs------------------------------------------------ 
 
 
 
Laboratory findings : 
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New symptom  after dug use : 
                                                                                                          
  
 ﺎﻧا ﺮﻗا .................... ﻦﻳﺮﺧﻼﻟ ﻪﺤﻠﺼﻣ ﻦﻣ ﺎﻬﻟ ﺎﻤﻟ ﻪﺳارﺪﻟا ﻩﺬه ﻲﻓ لﻮﺧﺪﻟا ﻲﻟﻮﺒﻘﺑ     . ﻊﻴﻗﻮﺘﻟا:  
                       
Before drug use :  
1.digoxin  level test: 
2.creatinin level test 
3.Liver function Test: 
1- T.Bilirubin,D. Bilirubin, 
2- Albumin 
3- Serum protein electrophoresis: 
4- Alkaline Phosphatase 
5- Alanine Aminotransferase (ALT) 
(GPT): 
6- Aspartate Aminotransferase (AST) 
(GOT): 
7-Globulin: 
c*electrolyte tests: 
1-sodiom (Na) 
2- calcium (Ca)  
3-potasiom (K) 
 
 
After dug use : 
1. digoxin  level test: 
2.creatinin level test 
3.Liver function Test: 
1- T.Bilirubin D. Bilirubin, 
2- Albumin: 
3- Serum protein electrophoresis: 
4- Alkaline Phosphatase: 
5- Alanine Aminotransferase (ALT) 
(GPT): 
6- Aspartate Aminotransferase (AST) 
(GOT): 
7-Globulin: 
c*electrolyte tests: 
1-sodiom (Na) 
2- calcium (Ca)        
3-potasiom (K) 
d* ECG in serious case 
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4.1. Clinical data 
Clinical data of patients with digoxin treatment included in study 68 male , and 52 
female, their  ages were between  (21- 96 years  ) . 
   Heart rates were between (80-125 bet /min  ) before  new macrolids therapy, and 
between (54-122 bet /min ) after new macrolids therapy .  
    Their systolic blood pressures were between (90-160 mm Hg) before new macrolids 
therapy , and between (60-160 mm Hg) after new macrolids therapy. 
Their diastolic blood pressures were (60-100 mm Hg) before new macrolids therapy , 
and between (40-110 mm Hg) after new macrolids therapy.  
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